[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1596
1. Kawabata G, Shimogaki H, Yamanaka K, Matsushita K, Takechi Y: Laparoscopic adrenalectomy: troublesome cases. Int J Urol; 2009 May;16(5):431
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Problems occurred due to the condition of the adrenal tumors themselves in six patients, whereas problems occurred due to the operative history in four patients.
  • In patients with bleeding in the adrenal tumors, large adrenal tumors, or tumors impacted in the liver, methods such as changing the sequence of separation procedures were required.
  • In patients with a history of renal subcapsular hematomas due to extracorporeal shock wave lithotripsy (ESWL), it was not possible to understand the conditions of adrenal or perinephritic adhesion in preoperative imaging diagnosis, but resection was possible by changing the order of separation procedures and by using optimal instruments and devices.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods. Cushing Syndrome / surgery. Laparoscopy / methods

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19467118.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Interactive Tutorial
  • [Publication-country] Australia
  •  go-up   go-down


2. Nürnberg D: [Ultrasound of adrenal gland tumours and indications for fine needle biopsy (uFNB)]. Ultraschall Med; 2005 Dec;26(6):458-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ultrasound of adrenal gland tumours and indications for fine needle biopsy (uFNB)].
  • [Transliterated title] Sonographie von Nebennierentumoren--wann ist die Punktion indiziert?
  • The normal adrenal glands can be detected by high-resolution-sonography in a high percentage of cases.
  • Sonography is also highly sensitive in the diagnosis of tumours of the adrenal glands.
  • Only some of those tumours are hormonally active.
  • Amongst the benign tumours, adenomas are the most frequent (up to 8%).
  • Amongst the malignant tumours, metastases are more frequent than primary carcinomas (32.5% vs. 19.8% in uFNB-statistics).
  • The adrenal glands are the fourth most common location of metastases.
  • Bronchiogenic carcinomas, malignant melanomas, carcinomas of the breast and stomach as well as renal carcinomas metastasize into the adrenals most often.
  • Much less frequent are infiltrates of lymphomas in adrenal glands tumours (3.4%).
  • Incidentalomas are accidentally detected tumours of the adrenal glands without clinical symptoms.
  • Malignant tumours only represent a very small part of incidentalomas (0.2%).
  • In the case of an accidentally detected tumour, we propose a minimal laboratory profile (24-h-urinary-catecholamines, dexamethasone-test, electrolyte metabolism).
  • The uFNB of the adrenal glands has a high sensitivity (90-95%).
  • Considering the excellent imaging methods and laparoscopic surgery methods on hand, the indication of FNP is restricted to the following cases: 1. the presence of a metastasis leading to therapeutical consequences; 2. suspected lymphoma 3. undefined lesion (3-5 cm), hormonally inactive, without typical signs of a tumour 4. patients refusing surgery.
  • 5. uFNB in case of tumours of undefined dignity is only justified in specific cases.
  • Recommendations for this procedure in accidentally detected tumours of the adrenal glands: < 3 cm and hormonally inactive --> US-follow up, > 5 cm + suspected tumour --> surgery, 3-5 cm uFNB after laboratory diagnostics.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / ultrasonography. Biopsy, Fine-Needle
  • [MeSH-minor] Adrenal Glands / cytology. Adrenal Glands / pathology. Adrenal Glands / ultrastructure. Humans. Lymphoma / pathology. Lymphoma / ultrasonography. Pheochromocytoma / pathology. Pheochromocytoma / ultrasonography

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16453217.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 116
  •  go-up   go-down


3. Inoue Y, True LD, Martins RG: Thymic carcinoma associated with paraneoplastic polymyositis. J Clin Oncol; 2009 Aug 1;27(22):e33-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Paraneoplastic Syndromes / etiology. Polymyositis / etiology. Thymoma / complications. Thymoma / pathology. Thymus Neoplasms / complications. Thymus Neoplasms / pathology
  • [MeSH-minor] Adrenal Cortex Hormones / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Disease Progression. Drug Therapy, Combination. Follow-Up Studies. Humans. Immunoglobulins, Intravenous / administration & dosage. Immunohistochemistry. Male. Neoplasm Invasiveness / pathology. Neoplasm Staging. Positron-Emission Tomography. Radiotherapy, Adjuvant. Rare Diseases. Risk Assessment. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Polymyositis.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 Aug 1;28(22):e378 [20458028.001]
  • (PMID = 19506156.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Immunoglobulins, Intravenous
  • [Number-of-references] 13
  •  go-up   go-down


Advertisement
4. Kola B, Grossman AB: Dynamic testing in Cushing's syndrome. Pituitary; 2008;11(2):155-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CS can be ACTH-dependent, caused by ACTH-secreting pituitary or ectopic tumours, or ACTH-independent, caused by cortisol-secreting adrenal tumours.
  • CS can be an extremely difficult diagnosis to make, and assessment will include clinical, biochemical and radiological evaluation.
  • We have reviewed the current literature on the diagnosis of CS, and based on these data and our own experience, suggest the most useful tests and diagnostic criteria to be used.
  • [MeSH-major] Cushing Syndrome / diagnosis. Pituitary Function Tests
  • [MeSH-minor] Adrenocorticotropic Hormone / physiology. Circadian Rhythm / physiology. Dexamethasone. Diagnosis, Differential. Humans. Hydrocortisone / blood. Hydrocortisone / urine. Saliva / chemistry

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3309-12 [10999826.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Dec;83(12):4207-11 [9851753.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Oct;91(10):3746-53 [16868050.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Aug;83(8):2681-6 [9709931.001]
  • [Cites] Trends Endocrinol Metab. 2004 Oct;15(8):375-82 [15380809.001]
  • [Cites] N Engl J Med. 1991 Sep 26;325(13):897-905 [1652686.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Nov;92(11):4290-3 [17635947.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jul;84(7):2489-95 [10404825.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Feb;80(2):412-7 [7852498.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Aug;82(8):2439-44 [9253314.001]
  • [Cites] Endocrinol Metab Clin North Am. 1994 Sep;23(3):539-46 [7805652.001]
  • [Cites] Clin Endocrinol (Oxf). 1995 Nov;43(5):545-50 [8548938.001]
  • [Cites] Clin Endocrinol (Oxf). 1991 Oct;35(4):361-7 [1721565.001]
  • [Cites] Front Horm Res. 2006;35:143-56 [16809930.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Mar;84(3):878-82 [10084565.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Apr;87(4):1646-53 [11932296.001]
  • [Cites] Lancet. 1968 Jun 8;1(7554):1234-6 [4172780.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Feb;66(2):251-7 [17223996.001]
  • [Cites] J Clin Endocrinol Metab. 1970 May;30(5):686-9 [4315484.001]
  • [Cites] Endocr Rev. 1998 Oct;19(5):647-72 [9793762.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Dec;88(12):5834-40 [14671177.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1222-6 [15001614.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):176-81 [8989255.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Aug;92(8):2972-6 [17488798.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Aug;92(8):3102-7 [17550962.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Dec;88(12):5593-602 [14671138.001]
  • [Cites] Eur J Endocrinol. 2007 Sep;157(3):271-7 [17766708.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Oct;81(10):3573-7 [8855803.001]
  • [Cites] Hormones (Athens). 2006 Oct-Dec;5(4):231-50 [17178699.001]
  • [Cites] Radiology. 1990 Aug;176(2):429-31 [2164235.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4153-7 [12970280.001]
  • [Cites] Lancet. 1999 Jun 19;353(9170):2087-8 [10382687.001]
  • [Cites] Acta Endocrinol (Copenh). 1985 Jun;109(2):158-62 [2990131.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):221-4 [16219718.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):418-22 [8106630.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jul;91(7):2582-6 [16670165.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Apr;83(4):1163-7 [9543134.001]
  • [Cites] Horm Metab Res. 1998 Jun-Jul;30(6-7):389-97 [9694568.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):487-92 [10022405.001]
  • [Cites] AJR Am J Roentgenol. 2006 Aug;187(2):562-70 [16861564.001]
  • [Cites] J Endocrinol Invest. 2007 Apr;30(4):334-40 [17556872.001]
  • [Cites] J Clin Endocrinol Metab. 1971 Feb;32(2):266-84 [4321505.001]
  • [Cites] Am J Med. 2005 Dec;118(12):1340-6 [16378774.001]
  • [Cites] Endocrinol Metab Clin North Am. 2005 Jun;34(2):441-58, x [15850852.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5299-306 [14602765.001]
  • [Cites] Ann Intern Med. 1986 Feb;104(2):180-6 [3004275.001]
  • [Cites] N Engl J Med. 1989 Dec 14;321(24):1659-64 [2586567.001]
  • [Cites] Lancet. 2006 May 13;367(9522):1605-17 [16698415.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Aug;89(8):3752-63 [15292301.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Oct;83(10):3624-30 [9768675.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jun;82(6):1780-5 [9177382.001]
  • [Cites] Br Med J (Clin Res Ed). 1984 Nov 3;289(6453):1188-91 [6437479.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12 ):5711-4 [11739426.001]
  • [Cites] Clin Endocrinol (Oxf). 1986 Jun;24(6):699-713 [3024870.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jun;81(6):2233-7 [8964857.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):440-8 [10022398.001]
  • [Cites] Am J Med. 1952 Nov;13(5):597-614 [12996538.001]
  • [Cites] Ann Clin Biochem. 1997 May;34 ( Pt 3):222-9 [9158818.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Apr;87(4):1640-5 [11932295.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Nov;77(5):1308-12 [8077325.001]
  • [Cites] JAMA. 1993 May 5;269(17):2232-8 [8386285.001]
  • [Cites] Endocrinol Metab Clin North Am. 2005 Jun;34(2):403-21, x [15850850.001]
  • [Cites] Acta Endocrinol (Copenh). 1990 Sep;123(3):331-8 [2239082.001]
  • [Cites] Horm Res. 2006;65(3):159-62 [16514243.001]
  • [Cites] J Chin Med Assoc. 2007 Jan;70(1):4-10 [17276926.001]
  • [Cites] Clin Endocrinol (Oxf). 1993 May;38(5):463-72 [8330442.001]
  • [Cites] Eur J Endocrinol. 2001 May;144(5):499-507 [11331216.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4515-21 [12364428.001]
  • [Cites] Metabolism. 1979 Sep;28(9):955-77 [225638.001]
  • [Cites] Eur J Endocrinol. 2005 Dec;153(6):803-9 [16322385.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Aug;92(8):2876-8 [17682087.001]
  • (PMID = 18034306.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 7S5I7G3JQL / Dexamethasone; 9002-60-2 / Adrenocorticotropic Hormone; WI4X0X7BPJ / Hydrocortisone
  • [Number-of-references] 71
  •  go-up   go-down


5. Ito T, Imai T, Kikumori T, Shibata A, Horiba T, Kobayashi H, Sawaki M, Watanabe R, Nakao A, Kiuchi T: Adrenal incidentaloma: review of 197 patients and report of a drug-related false-positive urinary normetanephrine result. Surg Today; 2006;36(11):961-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal incidentaloma: review of 197 patients and report of a drug-related false-positive urinary normetanephrine result.
  • PURPOSE: To determine the incidence and importance of functioning tumors among incidentally discovered adrenal masses in the era of laparoscopic surgery.
  • METHODS: We defined adrenal incidentaloma as a tumor detected during abdominal imaging for adrenal-unrelated reasons, and we reviewed 197 consecutive patients with adrenal incidentaloma diagnosed since we started laparoscopic adrenalectomy.
  • One patient, a 21-year-old woman taking mesalamine for ulcerative colitis, had a remarkably elevated urinary normetanephrine level, which resulted in the initial misdiagnosis of a 10-cm right adrenal incidentaloma as a pheochromocytoma.
  • Laparoscopic right adrenalectomy resulted in a pathological diagnosis of ganglioneuroma.
  • We found that other patients medicated with mesalamine, without adrenal tumors, had elevated urinary normetanephrine levels, confirming that mesalamine metabolites interfere with urinary normetanephrine measurements.
  • CONCLUSIONS: It is essential to diagnose the functional potential of adrenal incidentaloma preoperatively, and not to perform laparoscopic adrenalectomy for adrenal incidentaloma without careful evaluation first.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / urine. Biomarkers, Tumor / urine. Mesalamine / pharmacokinetics. Normetanephrine / urine. Pheochromocytoma / diagnosis. Pheochromocytoma / urine
  • [MeSH-minor] Adrenalectomy / methods. Adult. Anti-Inflammatory Agents, Non-Steroidal / pharmacokinetics. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Colitis, Ulcerative / drug therapy. Colitis, Ulcerative / urine. Diagnosis, Differential. False Positive Reactions. Female. Humans. Incidence. Laparoscopy. Male. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • Hazardous Substances Data Bank. MESALAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5130-7 [11701665.001]
  • [Cites] Clin Chem. 1999 Dec;45(12):2216-23 [10585355.001]
  • [Cites] Clin Chem. 2001 Jun;47(6):1061-7 [11375292.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):238-46; discussion 246-7 [9339930.001]
  • [Cites] Asian J Surg. 2003 Apr;26(2):64-70 [12732488.001]
  • [Cites] Am J Surg. 1999 Jul;178(1):50-3; discussion 54 [10456703.001]
  • [Cites] N Engl J Med. 1995 Feb 9;332(6):401 [7824012.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2656-66 [12788870.001]
  • [Cites] Biomed Pharmacother. 2002;56 Suppl 1:120s-125s [12487267.001]
  • [Cites] Ann Clin Biochem. 1984 Sep;21 ( Pt 5):446 [6508218.001]
  • [Cites] Surg Endosc. 1999 Apr;13(4):343-5 [10094744.001]
  • [Cites] Biomed Pharmacother. 2000 Jun;54 Suppl 1:140s-145s [10915011.001]
  • [Cites] World J Surg. 2001 Jul;25(7):905-13 [11572032.001]
  • [Cites] Ann Surg. 2001 Jul;234(1):85-91 [11420487.001]
  • [Cites] World J Surg. 1998 Jul;22(7):684-8 [9606282.001]
  • (PMID = 17072715.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Biomarkers, Tumor; 0J45DE6B88 / Normetanephrine; 4Q81I59GXC / Mesalamine
  •  go-up   go-down


6. Britvin TA, Kazantseva IA, Kalinin AP, Kushlinskii NE: Vascular endothelium growth factor in the sera of patients with adrenal tumors. Bull Exp Biol Med; 2005 Aug;140(2):228-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelium growth factor in the sera of patients with adrenal tumors.
  • Serum levels of vascular endothelium growth factor were measured in 43 patients with adrenal tumors and 25 healthy subjects.
  • The mean blood levels of the factor in patients with adrenal tumors significantly surpassed the control.
  • The levels of this factor were maximum in patients with adrenocortical cancer, but its mean level differed negligibly from that in other morphological variants of tumors.
  • A direct correlation was revealed between the level of vascular endothelium growth factor and tumor size in adrenocortical cancer and aldosterone-producing adenoma.
  • [MeSH-major] Adrenal Gland Neoplasms / blood. Gene Expression Regulation, Neoplastic. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16283008.001).
  • [ISSN] 0007-4888
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


7. Eto M, Harano M, Koga H, Tanaka M, Naito S: Clinical outcomes and learning curve of a laparoscopic adrenalectomy in 103 consecutive cases at a single institute. Int J Urol; 2006 Jun;13(6):671-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: We examined the clinical outcomes and the learning curve for a laparoscopic adrenalectomy (LA) in 103 consecutive cases performed by three surgeons at our institute, according to the type of adrenal disorder.
  • PATIENTS AND METHODS: One hundred and three patients with adrenal tumors, including 38 cases of primary aldosteronism, 33 cases of Cushing syndrome (including preclinical Cushing syndrome), 15 cases of pheochromocytoma, and nine cases of non-functioning adenoma were evaluated, while focusing on the approaches, intraoperative and postoperative data, and the learning curve of LA, according the type of adrenal disorder.
  • RESULTS: There was no significant difference in the operation time, estimated blood loss, incidence of conversion to open surgery and blood transfusion, or postoperative recovery among the patients treated by LA for aldosteronoma, Cushing adenoma, pheochromocytoma, and non-functioning adenoma.
  • On the other hand, in the cases treated by LA for pheochromocytoma, no trends in either the operation time or blood loss were observed.
  • However, there has been neither any conversion to open surgery nor blood transfusion in cases treated by LA since 1998 (our 42nd case), even after the changes in the operators.
  • CONCLUSIONS: Our results clearly indicate that LA is becoming safer than before, probably due to improvements in the technique, education, and training of surgeons, in addition to the increased number of cases now treated by LA.
  • [MeSH-major] Adrenal Gland Neoplasms / therapy. Adrenalectomy / education. Education, Medical, Continuing. Laparoscopy. Medical Staff, Hospital / education

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16834640.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


8. Hoff AO, Hauache OM: [Multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical and molecular diagnosis and treatment of the associated disturbances]. Arq Bras Endocrinol Metabol; 2005 Oct;49(5):735-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical and molecular diagnosis and treatment of the associated disturbances].
  • [Transliterated title] Neoplasia endócrina múltipla tipo 1: diagnóstico clínico, laboratorial e molecular e tratamento das doenças associadas.
  • Multiple endocrine neoplasia (MEN) syndromes include types 1 (MEN 1) and 2 (MEN 2), von Hippel-Lindau syndrome, neurofibromatosis type 1 and Carney complex.
  • MEN 1 is a hereditary syndrome, transmitted in an autosomic dominant fashion and caused by an inactivating mutation of the MEN 1 gene, characterized by the development of primary hyperparathyroidism, islet cell tumors and pituitary adenomas.
  • In addition, these patients can present with cutaneous manifestations such as angiofibromas and collagenomas, and can develop other neoplastic manifestations including carcinoids, thyroid tumors, adrenal adenomas, lipomas, pheochromocytomas and meningiomas.
  • The MEN 1 gene encodes a peptide which is a tumor suppressor gene called menin.
  • The discovery of the MEN 1 gene and the genetic analysis of MEN 1 patients have resulted in earlier diagnosis and treatment of asymptomatic carriers which can potentially result in a longer survival of these patients.
  • Further investigation of the function and signaling pathways of the menin protein will hopefully offer therapeutic alternatives to patients with malignant progression of MEN 1-related tumors and also result in improved survival.
  • [MeSH-major] Multiple Endocrine Neoplasia Type 1. Mutation / genetics. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Adenoma, Islet Cell / diagnosis. Adenoma, Islet Cell / genetics. Adenoma, Islet Cell / therapy. Genetic Testing. Humans. Hyperparathyroidism, Primary / diagnosis. Hyperparathyroidism, Primary / genetics. Hyperparathyroidism, Primary / therapy. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / therapy. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / genetics. Pituitary Neoplasms / therapy


9. Pecina-Slaus N, Nikuseva-Martic T, Gall-Troselj K, Radic K, Hrascan R: Replication error-positive samples found in pheochromocytomas. In Vivo; 2005 Mar-Apr;19(2):359-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenomatous polyposis coli, (APC) and E-cadherin (CDH1) tumor suppressor genes were investigated in human pheochromocytoma.
  • Interestingly, another type of genomic instability was detected--replication error-positive samples (RER+).
  • Four out of 13 heterozygous samples were RER-positive (30.8%).
  • Immunohistochemistry showed increased levels of c-myc in comparison to normal adrenal tissue.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Cadherins / genetics. Genes, APC. Genomic Instability. Pheochromocytoma / genetics
  • [MeSH-minor] Adult. Aged. DNA, Neoplasm / genetics. Female. Humans. Loss of Heterozygosity. Male. Middle Aged. Proto-Oncogene Proteins c-myc / biosynthesis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15796198.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cadherins; 0 / DNA, Neoplasm; 0 / Proto-Oncogene Proteins c-myc
  •  go-up   go-down


10. Majumdar S, Friedrich CA, Koch CA, Megason GC, Fratkin JD, Moll GW: Compound heterozygous mutation with a novel splice donor region DNA sequence variant in the succinate dehydrogenase subunit B gene in malignant paraganglioma. Pediatr Blood Cancer; 2010 Mar;54(3):473-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pheochromocytoma and paraganglioma (PGL) are rare neuroendocrine tumors in children.
  • SDHB mutations are associated with malignant disease.
  • Family history was positive for non-classical congenital adrenal hyperplasia and pituitary adenoma.
  • At 3-year follow-up, he had stable disease.
  • [MeSH-major] Brain Neoplasms / genetics. DNA, Neoplasm / genetics. Germ-Line Mutation. Mutation, Missense. Paraganglioma / genetics. Succinate Dehydrogenase / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • [CommentIn] Pediatr Blood Cancer. 2010 Jul 15;55(1):211; author reply 212 [20213850.001]
  • (PMID = 19927285.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / RNA Splice Sites; EC 1.3.99.1 / Succinate Dehydrogenase
  •  go-up   go-down


11. Ozben B, Papila N, Tanrikulu MA, Bayalan F, Fak AS, Oktay A: Inferior vena caval tumor thrombus extending into the right atrium in a patient with pancreatic cancer. J Thromb Thrombolysis; 2007 Dec;24(3):317-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inferior vena caval tumor thrombus extending into the right atrium in a patient with pancreatic cancer.
  • While deep venous thrombosis and pulmonary embolism are the most common thrombotic conditions in patients with malignant disease, tumor thrombus may be seen in inferior vena cava, mainly in patients with renal cell carcinoma, hepatocellular carcinoma, testicular tumors or adrenal carcinoma.
  • We report a female patient with pancreatic cancer associated with tumor thrombus extending from the inferior vena cava to the right atrium.
  • [MeSH-major] Pancreatic Neoplasms / complications. Vena Cava, Inferior / pathology. Venous Thromboembolism / etiology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Vasc Surg. 2006 Mar;20(2):223-7 [16550482.001]
  • [Cites] Cancer. 1954 May;7(3):462-503 [13160935.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Nov;33(11):1653-6 [17108735.001]
  • [Cites] J Urol. 1987 Jan;137(1):21-4 [3795361.001]
  • [Cites] Surgery. 1991 Feb;109 (2):214-9 [1846985.001]
  • [Cites] Arch Esp Urol. 2003 Jun;56(5):485-9 [12918305.001]
  • [Cites] N Engl J Med. 1996 Sep 19;335(12):865-75 [8778606.001]
  • [Cites] J Med Invest. 2000 Aug;47(3-4):155-60 [11019497.001]
  • [Cites] JAMA. 1961 Aug 26;177:542-5 [13762005.001]
  • [Cites] Urol Oncol. 2003 Sep-Oct;21(5):327-33 [14670538.001]
  • [Cites] Semin Oncol. 1990 Apr;17(2):147-59 [2183357.001]
  • [Cites] Circulation. 2003 Jun 17;107(23 Suppl 1):I17-21 [12814981.001]
  • [Cites] Cancer Invest. 2001;19(1):65-75 [11291558.001]
  • [Cites] Thromb Haemost. 2002 Jun;87(6):1076-7 [12083490.001]
  • [Cites] Medicine (Baltimore). 1999 Sep;78(5):285-91 [10499070.001]
  • [Cites] Ann Thorac Surg. 1997 Jun;63(6):1592-600 [9205155.001]
  • [Cites] Chin Med J (Engl). 2006 Nov 20;119(22):1934-6 [17134595.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):677-81 [8594425.001]
  • [Cites] J Surg Oncol. 1995 Jun;59(2):94-100 [7776659.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):212-6 [15783033.001]
  • [Cites] Ann Surg. 1989 Sep;210(3):387-92; discussion 392-4 [2774709.001]
  • [Cites] Urology. 1995 Dec;46(6):883-7 [7502438.001]
  • [Cites] Semin Thromb Hemost. 1999;25(2):137-45 [10357081.001]
  • [Cites] J Am Coll Surg. 2002 Dec;195(6):892-4 [12495323.001]
  • [Cites] Eur Urol. 1992;21(1):82-4 [1318844.001]
  • [Cites] Hepatogastroenterology. 1997 May-Jun;44(15):824-5 [9222699.001]
  • [Cites] Echocardiography. 2002 Feb;19(2):149-51 [11926979.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1374-7 [12352396.001]
  • [Cites] Prog Urol. 2002 Sep;12(4):668-71 [12463131.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Hepatogastroenterology. 1994 Apr;41(2):154-7 [8056404.001]
  • [Cites] Int J Urol. 2006 Aug;13(8):1144-6 [16903951.001]
  • [Cites] Abdom Imaging. 1994 Jul-Aug;19(4):313-6 [8075552.001]
  • [Cites] Ann Surg. 1996 Mar;223(3):273-9 [8604907.001]
  • [Cites] Medicine (Baltimore). 1977 Jan;56(1):1-37 [834136.001]
  • [Cites] Pancreas. 2004 Apr;28(3):301-4 [15084976.001]
  • [Cites] Int J Urol. 2005 May;12(5):513-5 [15948757.001]
  • [Cites] Teratog Carcinog Mutagen. 2001;21(1):7-25 [11135318.001]
  • [Cites] J Vasc Surg. 2001 Apr;33(4):789-96 [11296333.001]
  • [Cites] Circulation. 1997 Oct 21;96(8):2729-30 [9355916.001]
  • [Cites] Arch Intern Med. 2000 Mar 27;160(6):809-15 [10737280.001]
  • [Cites] Ann Thorac Surg. 2001 Feb;71(2):733-4 [11235750.001]
  • [Cites] J Urol. 1984 Dec;132(6):1097-100 [6502795.001]
  • [Cites] Urology. 2004 Feb;63(2):380-2 [14972500.001]
  • (PMID = 17483876.001).
  • [ISSN] 0929-5305
  • [Journal-full-title] Journal of thrombosis and thrombolysis
  • [ISO-abbreviation] J. Thromb. Thrombolysis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


12. Komai Y, Kawakami S, Yoshida S, Sakai Y, Kobayashi T, Kageyama Y, Kihara K: [A case of cystic ganglioneuroma of adrenal gland presenting as a huge retroperitoneal mass]. Hinyokika Kiyo; 2006 Jul;52(7):549-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of cystic ganglioneuroma of adrenal gland presenting as a huge retroperitoneal mass].
  • Imaging studies demonstrated a bulky tumor with cyst formation measuring 22 cm.
  • Preoperative differential diagnoses included an adrenal tumor, extra-adrenal retroperitoneal tumor and pancreatic mucinous tumor.
  • A tight adhesion of the tumor to the left kidney necessitated an en bloc resection of the tumor with the left kidney.
  • Pathologically, the tumor was ganglioneuroma originating from the left adrenal gland.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Ganglioneuroma / pathology. Retroperitoneal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Cysts / diagnosis. Cysts / pathology. Cysts / surgery. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910588.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Kodama H, Iihara M, Nissato S, Isobe K, Kawakami Y, Okamoto T, Takekoshi K: A large deletion in the succinate dehydrogenase B gene (SDHB) in a Japanese patient with abdominal paraganglioma and concomitant metastasis. Endocr J; 2010;57(4):351-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Gene Deletion. Paraganglioma, Extra-Adrenal / genetics. Succinate Dehydrogenase / genetics
  • [MeSH-minor] Adult. Catecholamines / blood. DNA / blood. DNA / chemistry. Exons / genetics. Female. Heterozygote. Humans. Hypertension. Liver Neoplasms / secondary. Neoplasm Metastasis. Neoplasm Recurrence, Local / diagnosis. Norepinephrine / blood. Normetanephrine / urine. Para-Aortic Bodies. Polymerase Chain Reaction. Promoter Regions, Genetic / genetics. Sequence Analysis, DNA. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. Norepinephrine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20379037.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Catecholamines; 0J45DE6B88 / Normetanephrine; 9007-49-2 / DNA; EC 1.3.5.1 / SDHB protein, human; EC 1.3.99.1 / Succinate Dehydrogenase; X4W3ENH1CV / Norepinephrine
  •  go-up   go-down


14. Pellkofer HL, Voltz R, Goebels N, Hohlfeld R, Dornmair K: Cross-reactive T-cell receptors in tumor and paraneoplastic target tissue. Arch Neurol; 2009 May;66(5):655-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cross-reactive T-cell receptors in tumor and paraneoplastic target tissue.
  • BACKGROUND: According to established criteria, paraneoplastic encephalomyelitis with adrenal neuroblastoma comprises a definite paraneoplastic neurologic syndrome.
  • OBJECTIVE: To detect T-cell clones that cross-react against antigens shared between tumor and nervous system.
  • Patient A 22-year-old woman having paraneoplastic encephalomyelitis with adrenal neuroblastoma.
  • MAIN OUTCOME MEASURES: We compared the T-cell receptor repertoires expressed in blood, cerebrospinal fluid, and neuroblastoma tumor tissue using complementary determining region 3 (CDR3) spectratyping and clone-specific polymerase chain reaction.
  • RESULTS: The T-cell receptor repertoire in cerebrospinal fluid was narrow compared with that in tumor and blood.
  • They recognize the same antigen in nervous system and tumor tissue and represent an attractive target for selective therapy.
  • [MeSH-major] Adrenal Gland Neoplasms / immunology. Neuroblastoma / immunology. Paraneoplastic Syndromes, Nervous System / immunology. Receptors, Antigen, T-Cell / analysis
  • [MeSH-minor] Antigens, Neoplasm / analysis. Antigens, Neoplasm / classification. Biomarkers / analysis. Biomarkers / blood. Biomarkers / cerebrospinal fluid. Cell Lineage / immunology. Clone Cells / immunology. Cross Reactions / immunology. Female. Humans. Immunophenotyping. Lymphocyte Activation / immunology. Receptors, Antigen, T-Cell, alpha-beta / analysis. T-Lymphocyte Subsets / immunology. T-Lymphocytes / classification. T-Lymphocytes / immunology. Young Adult

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Neurol. 2009 Oct;66(10):1299-300; author reply 300 [19822792.001]
  • (PMID = 19433667.001).
  • [ISSN] 1538-3687
  • [Journal-full-title] Archives of neurology
  • [ISO-abbreviation] Arch. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers; 0 / Receptors, Antigen, T-Cell; 0 / Receptors, Antigen, T-Cell, alpha-beta
  •  go-up   go-down


15. Lombardi CP, Raffaelli M, Pani G, Maffione A, Princi P, Traini E, Galeotti T, Rossi ED, Fadda G, Bellantone R: Gene expression profiling of adrenal cortical tumors by cDNA macroarray analysis. Results of a preliminary study. Biomed Pharmacother; 2006 May;60(4):186-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling of adrenal cortical tumors by cDNA macroarray analysis. Results of a preliminary study.
  • Adrenocortical carcinoma (ACC) are highly malignant tumors with poor prognosis.
  • To verify if it is possible to assess their differential gene expression by a cDNA macroarray analysis using RNA extracted from paraffin sections, we analyzed two different cohorts of adrenal cortical adenoma (ACA) and ACC.
  • Heat shock protein 60 (HSP-60) (ratio>2), Ciclin D1 and topoisomerase I (ratio>1.5) were overexpressed in the ACC cohort, while jun proto-oncogene was down-regulated. cDNA macroarray analysis from paraffin sections of adrenal tumors is feasible, despite with a low success rate.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Adrenocortical Carcinoma / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic / genetics. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Down-Regulation. Humans. Neoplasm Proteins / genetics. Up-Regulation


16. Wang H, Zhou FJ, Qin ZK, Han H, Liu ZW: [Laparoscopic surgery for benign adrenal tumor: a report of 10 cases]. Ai Zheng; 2005 Jan;24(1):76-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic surgery for benign adrenal tumor: a report of 10 cases].
  • BACKGROUND & OBJECTIVE: Adrenalectomy is a standard treatment for benign adrenal tumors.
  • Conventional open operation usually results in bigger incisions, more blood loss, and long hospital stay to patients; while laparoscopic approaches could make up above shortcomings, which is used to resect benign adrenal tumors gradually.
  • METHODS: Clinical data of 10 patients with benign adrenal tumors undergone laparoscopic adrenalectomy were retrospectively analyzed to summarize the experiences and techniques in laparoscopic surgery.
  • RESULTS: Of the 10 patients, 9 had tumors successfully resected by laparoscopic adrenalectomy with no severe postoperative complication; 1 switched to receive open surgery during operation, and had mild postoperative corticoadrenal insufficiency.
  • CONCLUSION: Laparoscopic surgery for treatment of benign adrenal tumors has the advantages of minimal invasion, safety, and efficiency, and may be a primary therapeutic option for benign adrenal tumors.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods. Laparoscopy. Pheochromocytoma / surgery

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15642205.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


17. Müller-Horvat C, Radny P, Eigentler TK, Schäfer J, Pfannenberg C, Horger M, Khorchidi S, Nägele T, Garbe C, Claussen CD, Schlemmer HP: Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. Eur J Cancer; 2006 Feb;42(3):342-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patient management and treatment strategies for metastatic melanoma depend largely on the stage of metastatic disease.
  • In kidneys, adrenal glands and lymph nodes, respectively, wbCT and wbMRI detected the same number of lesions.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Melanoma / diagnosis. Skin Neoplasms / diagnosis. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Decision Making. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis / diagnosis. Neoplasm Staging / methods. Prognosis. Prospective Studies

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16364631.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Engelman E, Maeyens C: Effect of preoperative single-dose corticosteroid administration on postoperative morbidity following esophagectomy. J Gastrointest Surg; 2010 May;14(5):788-804
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Esophageal Neoplasms / mortality. Esophageal Neoplasms / surgery. Methylprednisolone / administration & dosage. Postoperative Complications / prevention & control. Preoperative Care
  • [MeSH-minor] Adrenal Cortex Hormones / administration & dosage. Adrenal Cortex Hormones / adverse effects. Dose-Response Relationship, Drug. Esophagectomy / adverse effects. Esophagectomy / methods. Female. Follow-Up Studies. Humans. Male. Neoplasm Invasiveness / pathology. Neoplasm Staging. Randomized Controlled Trials as Topic. Risk Assessment. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Thromb Hemost. 2004 Feb;30(1):63-9 [15034798.001]
  • [Cites] J Am Coll Surg. 2009 Feb;208(2):269-78 [19228539.001]
  • [Cites] Hepatogastroenterology. 2004 Jul-Aug;51(58):994-7 [15239232.001]
  • [Cites] J Am Coll Surg. 2006 Mar;202(3):439-44 [16500248.001]
  • [Cites] Eur J Surg. 1997 Jul;163(7):511-7 [9248985.001]
  • [Cites] Development. 1996 Jul;122(7):2251-9 [8681805.001]
  • [Cites] Ann Thorac Surg. 2003 Jan;75(1):217-22; discussion 222 [12537219.001]
  • [Cites] Dis Colon Rectum. 2009 Jun;52(6):1080-8 [19581850.001]
  • [Cites] FASEB J. 1999 Jul;13(10):1231-8 [10385613.001]
  • [Cites] Br J Anaesth. 2000 Jul;85(1):109-17 [10927999.001]
  • [Cites] J Gastrointest Surg. 2009 Sep;13(9):1558-60 [19415398.001]
  • [Cites] Eur J Appl Physiol. 2009 Jan;105(2):309-13 [18985374.001]
  • [Cites] J Surg Res. 1998 Oct;79(2):158-63 [9758732.001]
  • [Cites] Nature. 1973 Apr 6;242(5397):399-401 [4349600.001]
  • [Cites] Circulation. 1994 Aug;90(2):649-52 [8044933.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(5):484-92 [17909718.001]
  • [Cites] Arch Surg. 2001 Mar;136(3):328-33 [11231856.001]
  • [Cites] Liver Transpl. 2006 Jun;12(6):941-9 [16710858.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 22;98(11):6390-5 [11344271.001]
  • [Cites] J Biol Chem. 1992 Sep 25;267(27):19555-9 [1326558.001]
  • [Cites] Res Vet Sci. 2007 Apr;82(2):187-94 [17014872.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Jul;112(1):142-5 [8691860.001]
  • [Cites] Endocrinology. 1965 May;76:916-27 [14290154.001]
  • [Cites] Pharmacol Res. 2002 Apr;45(4):299-304 [12030793.001]
  • [Cites] Ann Surg. 1993 Dec;218(6):769-76 [8257227.001]
  • [Cites] Surgery. 2000 Nov;128(5):791-8 [11056442.001]
  • [Cites] Ann Surg. 2002 Aug;236(2):184-90 [12170023.001]
  • [Cites] J Thorac Cardiovasc Surg. 2009 Mar;137(3):587-95; discussion 596 [19258071.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Oct;108(4):626-35 [7934095.001]
  • [Cites] J Biol Chem. 1993 Sep 5;268(25):18966-74 [8360185.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(8):2830-41 [11909975.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Proc Natl Acad Sci U S A. 1973 Sep;70(9):2702-6 [4354860.001]
  • [Cites] J Gastrointest Surg. 2008 Oct;12(10):1762-70; discussion 1771-2 [18709424.001]
  • [Cites] Am Surg. 2008 Feb;74(2):160-7 [18306871.001]
  • [Cites] World J Surg. 2000 Jun;24(6):705-11 [10773123.001]
  • [Cites] Am J Surg. 1980 Mar;139(3):406-13 [6987913.001]
  • [Cites] Microvasc Res. 2003 Sep;66(2):102-12 [12935768.001]
  • [Cites] Eur J Surg Oncol. 2009 Aug;35(8):820-5 [19195816.001]
  • [Cites] J Gastrointest Surg. 2010 Feb;14 Suppl 1:S101-7 [19774427.001]
  • [Cites] Eur J Surg. 1999 Oct;165(10):971-8 [10574107.001]
  • [Cites] Anesthesiology. 2008 Dec;109(6):1023-35 [19034099.001]
  • [Cites] J Cell Biochem. 2006 Sep 1;99(1):187-95 [16598785.001]
  • [Cites] Ital J Surg Sci. 1988;18(4):369-75 [3147971.001]
  • [Cites] Int Surg. 1996 Jan-Mar;81(1):49-51 [8803706.001]
  • [Cites] Br J Surg. 2003 Jan;90(1):17-22 [12520569.001]
  • [Cites] J Am Coll Surg. 2004 Jan;198(1):42-50 [14698310.001]
  • [Cites] Anesth Analg. 2007 Dec;105(6):1615-28, table of contents [18042859.001]
  • [Cites] Circ Shock. 1978;5(4):415-22 [378452.001]
  • [Cites] Mol Cell Biol. 2007 Mar;27(6):2411-22 [17220278.001]
  • [Cites] J Am Coll Surg. 2002 Nov;195(5):694-712 [12437261.001]
  • [Cites] Arch Surg. 1997 Feb;132(2):129-35 [9041914.001]
  • [Cites] Hepatogastroenterology. 2005 Mar-Apr;52(62):481-5 [15816462.001]
  • [Cites] Dig Liver Dis. 2006 Apr;38(4):240-4 [16533623.001]
  • [Cites] J Thromb Haemost. 2005 Aug;3(8):1835-42 [16102050.001]
  • [Cites] J Cell Physiol. 1978 Apr;95(1):13-22 [565362.001]
  • [Cites] Am J Physiol. 1995 Aug;269(2 Pt 2):H686-95 [7653633.001]
  • [Cites] J Cell Biochem. 2001;82(4):591-8 [11500937.001]
  • [Cites] Surgery. 2008 Apr;143(4):499-508 [18374047.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:333-61 [9442877.001]
  • [Cites] BMC Gastroenterol. 2005 Nov 21;5:37 [16300680.001]
  • [Cites] Eur Surg Res. 2009;42(4):249-57 [19346745.001]
  • [Cites] Control Clin Trials. 1996 Feb;17(1):1-12 [8721797.001]
  • [Cites] J Nippon Med Sch. 2003 Feb;70(1):16-20 [12646971.001]
  • [Cites] J Gastrointest Surg. 2005 Feb;9(2):291-310 [15694827.001]
  • [Cites] J Clin Invest. 1993 Jan;91(1):94-8 [8380817.001]
  • [Cites] J Pediatr Surg. 2008 Feb;43(2):290-5 [18280276.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1711-23 [16236742.001]
  • [Cites] Acta Anaesthesiol Scand. 2007 Oct;51(9):1133-5 [17850557.001]
  • [Cites] J Biol Chem. 1997 Jul 4;272(27):17097-103 [9202027.001]
  • [Cites] Ann Surg. 2007 Sep;246(3):363-72; discussion 372-4 [17717440.001]
  • [Cites] Surg Clin North Am. 1997 Jun;77(3):549-73 [9194880.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Oct;126(4):1162-7 [14566263.001]
  • [Cites] Ann Thorac Surg. 1996 Jul;62(1):184-90 [8678641.001]
  • [Cites] FASEB J. 2002 Aug;16(10):1316-8 [12060671.001]
  • [Cites] Diabetes. 2004 Sep;53(9):2443-8 [15331557.001]
  • [Cites] J Biol Chem. 1974 Oct 10;249(19):6099-103 [4472604.001]
  • [Cites] World J Surg. 2003 Apr;27(4):465-72 [12658494.001]
  • (PMID = 20229072.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; X4W7ZR7023 / Methylprednisolone
  • [Number-of-references] 83
  •  go-up   go-down


19. Thoren KL, Balingit AG, Billingsley J: Multiple pheochromocytomas in a patient with blurred vision. Clin Nucl Med; 2008 Sep;33(9):597-601
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple imaging was obtained because of concern for von Hippel-Lindau disease (VHL) after bilateral retinal angiomas were discovered on ophthalmologic consultation as a follow-up from the Emergency Department.
  • Computed tomography (CT) and magnetic resonance imaging (MRI) were able to localize the adrenal and extra-adrenal tumors; however, accurate differentiation between pheochromocytomas and other adrenal tumors was not possible.
  • I-123 MIBG was performed before surgery to confirm that the lesions were indeed pheochromocytomas and also to rule out metastatic disease.
  • He was presented in urology tumor board conference with recommendations for follow-up CT and laboratory tests after 3 months.
  • [MeSH-major] Pheochromocytoma / complications. Pheochromocytoma / diagnosis. Vision Disorders / complications. Vision Disorders / diagnosis

  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18716506.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 35MRW7B4AD / 3-Iodobenzylguanidine
  •  go-up   go-down


20. Al-Hawary MM, Francis IR, Korobkin M: Non-invasive evaluation of the incidentally detected indeterminate adrenal mass. Best Pract Res Clin Endocrinol Metab; 2005 Jun;19(2):277-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-invasive evaluation of the incidentally detected indeterminate adrenal mass.
  • Clinically silent adrenal masses are discovered incidentally during diagnostic testing or treatment for clinical conditions that are not related to suspicion of adrenal disease; thus, they are commonly referred to as 'incidentalomas'.
  • In many patients without a known extra-adrenal primary malignancy--and even in patients with a primary neoplasm--most adrenal masses ultimately prove to be benign.
  • However, it remains important that these adrenal masses are accurately characterized to exclude the treatable causes of adrenal disease, and also to accurately stage the oncology patient.
  • The purpose of this chapter is to describe the findings and recent advances in non-invasive imaging methods that are now available for the accurate characterization of incidentally detected adrenal masses (i.e. the differentiation of benign from malignant masses).
  • The imaging techniques and the algorithms that are used in our institution for the evaluation of incidentally detected adrenal mass will be described.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenocortical Adenoma / diagnosis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15763701.001).
  • [ISSN] 1521-690X
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 47
  •  go-up   go-down


21. Bedke J, Buse S, Pritsch M, Macher-Goeppinger S, Schirmacher P, Haferkamp A, Hohenfellner M: Perinephric and renal sinus fat infiltration in pT3a renal cell carcinoma: possible prognostic differences. BJU Int; 2009 May;103(10):1349-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perinephric and renal sinus fat infiltration in pT3a renal cell carcinoma: possible prognostic differences.
  • OBJECTIVE: To evaluate the influence of perinephric (PN) and renal sinus (RS) fat infiltration on cancer-specific survival beyond other prognostic factors, as the Tumour-Node-Metastasis (TNM) classification system defines stage T3a renal cell carcinoma (RCC) as infiltration of perirenal fat and/or direct infiltration of the adrenal gland.
  • To identify prognostic effects of PN, RS or RS + PN fat infiltration, univariable and multivariable Cox proportional hazard regression models were applied, including lymph node status, metastases, presence of sarcomatoid features and tumour necrosis, Fuhrman's grade, Karnofsky performance status, and tumour size.
  • [MeSH-major] Adipose Tissue / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Nephrectomy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Epidemiologic Methods. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19076147.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. Leyssens B, Wildiers H, Lobelle JP, Gillis A, Paridaens R, Mombaerts I: A double-blind randomized phase II study on the efficacy of topical eye treatment in the prevention of docetaxel-induced dacryostenosis. Ann Oncol; 2010 Feb;21(2):419-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A double-blind randomized phase II study on the efficacy of topical eye treatment in the prevention of docetaxel-induced dacryostenosis.
  • BACKGROUND: Dacryostenosis is a common side-effect of weekly docetaxel (Taxotere).
  • We investigate the efficacy of eyedrops containing corticosteroids (CS) versus artificial tears (AT) in patients receiving weekly docetaxel in the prevention of dacryostenosis.
  • PATIENTS AND METHODS: Twenty patients receiving weekly docetaxel were evaluated.
  • Forty eyes were double-blind randomized: AT in one eye and CS in the other eye were administered, six times daily, throughout the docetaxel administration.
  • Patients were assessed for tearing and stenosis at weeks 3, 6, 9 and 26.
  • The primary end point was the incidence of dacryostenosis in each group at 9 weeks.
  • RESULTS: At 9 weeks, punctal or canalicular stenosis was observed in 9 of 20 (45%) of the CS eyes and 9 of 20 (45%) of the AT eyes.
  • Dacryostenosis was mild in 37 of 40 eyes (93%) and severe in 3 of 40 eyes (8%), with equal distribution in the CS and AT group.
  • Tearing was present in 9 of 20 (45%) of the CS eyes and 8 of 20 (40%) of the AT eyes, of which two eyes without stenosis in each group.
  • CONCLUSIONS: The incidence of dacryostenosis in patients receiving weekly docetaxel was not different for the AT- and the CS-treated eyes.
  • The dacryostenosis was predominantly mild, not leading to surgical interventions.

  • MedlinePlus Health Information. consumer health - Steroids.
  • MedlinePlus Health Information. consumer health - Tears.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19622592.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antineoplastic Agents; 0 / Ophthalmic Solutions; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


23. Grever MR, Lucas DM, Johnson AJ, Byrd JC: Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. Best Pract Res Clin Haematol; 2007 Sep;20(3):545-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A subset of patients with high-risk CLL rapidly progress to develop symptomatic disease requiring treatment.
  • Over-represented in this group are those who have a deletion of 17p13.1, the chromosomal location of the tumor suppressor gene P53.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Tumor Suppressor Protein p53 / deficiency
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / therapeutic use. Apoptosis / drug effects. CD40 Ligand / therapeutic use. Chromosomes, Human, Pair 17. Combined Modality Therapy. Flavonoids / therapeutic use. Gene Deletion. Humans. Middle Aged. Piperidines / therapeutic use

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17707839.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA81534-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Flavonoids; 0 / Piperidines; 0 / Tumor Suppressor Protein p53; 147205-72-9 / CD40 Ligand; 3A189DH42V / alemtuzumab; 45AD6X575G / alvocidib
  •  go-up   go-down


24. Meyer-Rochow GY, Soon PS, Delbridge LW, Sywak MS, Bambach CP, Clifton-Bligh RJ, Robinson BG, Sidhu SB: Outcomes of minimally invasive surgery for phaeochromocytoma. ANZ J Surg; 2009 May;79(5):367-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Laparoscopic adrenalectomy is now accepted as the procedure of choice for the resection of benign adrenocortical tumours, but few studies have assessed whether the outcomes of laparoscopic adrenalectomy for adrenal phaeochromocytoma are similar to that of other adrenal tumour types.
  • Clinical and operative data were obtained from an adrenal tumour database and hospital records.
  • Despite the greater size of the phaeochromocytomas compared to the remaining adrenal tumour types (44 mm vs 30 mm, P < 0.01), however, rate of conversion and morbidity were no different.
  • Laparoscopic adrenalectomy for phaeochromocytoma is a safe procedure with similar outcomes to laparoscopic adrenalectomy for other adrenal tumour types.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods. Laparoscopy / methods. Pheochromocytoma / surgery

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19566519.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


25. Ambika S, Melton A, Lee D, Hesketh PJ: Massive retroperitoneal adrenal hemorrhage secondary to lung cancer metastasis treated by adrenal artery embolization. Clin Lung Cancer; 2009 Sep;10(5):E1-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massive retroperitoneal adrenal hemorrhage secondary to lung cancer metastasis treated by adrenal artery embolization.
  • The development of adrenal hemorrhage from lung cancer metastasis is extremely rare.
  • A 54-year-old woman with stage IV non-small-cell lung cancer and known bilateral adrenal metastasis developed severe right-sided abdominal pain while undergoing chemotherapy treatment.
  • The bleeding vessel was identified as the right middle adrenal artery.
  • The patient underwent successful transcatheter embolization (TCE) and occlusion of the right middle adrenal artery using metallic coils, with resolution of the abdominal pain and stabilization of her hemoglobin.
  • TCE can be used to control hemorrhage arising from metastatic involvement of the adrenal gland.
  • [MeSH-major] Adrenal Gland Neoplasms / drug therapy. Adrenal Gland Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / secondary. Catheterization, Peripheral. Embolization, Therapeutic. Hemorrhage / chemically induced. Hemorrhage / therapy. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology
  • [MeSH-minor] Adrenal Glands / blood supply. Adrenal Glands / pathology. Carboplatin / administration & dosage. Carboplatin / adverse effects. Diagnostic Imaging. Female. Flank Pain. Glutamates / administration & dosage. Glutamates / adverse effects. Guanine / administration & dosage. Guanine / adverse effects. Guanine / analogs & derivatives. Humans. Male. Middle Aged. Neoplasm Staging. Pemetrexed. Retroperitoneal Space / pathology


26. Shibata H: [Corticosterone-producing adrenal tumor]. Nihon Rinsho; 2006 May 28;Suppl 1:638-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Corticosterone-producing adrenal tumor].
  • [MeSH-major] Adenoma / metabolism. Adrenal Gland Neoplasms / metabolism. Corticosterone / biosynthesis
  • [MeSH-minor] Adrenalectomy. Diagnosis, Differential. Humans. Hypertension / drug therapy. Hypertension / etiology. Hyponatremia / etiology. Metyrapone / therapeutic use. Mineralocorticoid Receptor Antagonists / therapeutic use. Prognosis. Spironolactone / therapeutic use

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • Hazardous Substances Data Bank. SPIRONOLACTONE .
  • Hazardous Substances Data Bank. METYRAPONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16776236.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Mineralocorticoid Receptor Antagonists; 27O7W4T232 / Spironolactone; W980KJ009P / Corticosterone; ZS9KD92H6V / Metyrapone
  • [Number-of-references] 13
  •  go-up   go-down


27. Just PA, Tissier F, Silvera S, Dousset B, Ballet S, Delattre O, Vacher-Lavenu MC, Goldwasser F, Bertagna X, De Pinieux G: Unexpected diagnosis for an adrenal tumor: synovial sarcoma. Ann Diagn Pathol; 2010 Feb;14(1):56-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unexpected diagnosis for an adrenal tumor: synovial sarcoma.
  • A 39-year-old woman presented with an incidentally discovered mass of the left adrenal fossa.
  • Immunohistochemistry using anticytokeratin showed some epithelial cells within the tumor.
  • The diagnosis of primitive synovial sarcoma of the left adrenal fossa was confirmed by the presence of the characteristic t(X;18) translocation.
  • Despite radiotherapy, several chemotherapies, and 2 other surgical resections, the patient died 30 months after the initial diagnosis.
  • To our knowledge, this report constitutes the first described case of synovial sarcoma arising in the adrenal gland.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Adrenal Glands / pathology. Magnetic Resonance Imaging. Sarcoma, Synovial / pathology

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010. Published by Elsevier Inc.
  • (PMID = 20123459.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Berruti A, Terzolo M, Sperone P, Pia A, Della Casa S, Gross DJ, Carnaghi C, Casali P, Porpiglia F, Mantero F, Reimondo G, Angeli A, Dogliotti L: Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer; 2005 Sep;12(3):657-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the activity of etoposide, doxorubicin, and cisplatin plus mitotane in the management of advanced adrenocortical carcinoma (ACC) patients, 72 patients with measurable disease not amenable to radical surgery were enrolled in a prospective, multicenter phase II trial.
  • Radical surgical resection of residual disease after chemotherapy was performed in 10 patients.
  • The overall survival of patients attaining a disease free status (clinical complete responders+radically resected) was significantly higher than that of patients with partial response or no response (P<0.002).
  • Surgical resection of residual disease subsequent to chemotherapy leads to a more favourable outcome.
  • The natural history of the disease is significantly influenced by the secretory status of the tumor.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Cisplatin / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Injections, Intravenous. Male. Middle Aged. Mitotane / administration & dosage. Neoplasm Staging. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16172198.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 78E4J5IB5J / Mitotane; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


29. Pomara G, Cappello F, Barzon L, Morelli G, Rappa F, Benvegna L, Giannarini G, Palù G, Selli C: Cytomegalovirus and BK-Virus co-infection of a clinically non-functioning adrenal adenoma: innocent bystanders or new pathogenetic agents? Eur J Histochem; 2006 Apr-Jun;50(2):131-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomegalovirus and BK-Virus co-infection of a clinically non-functioning adrenal adenoma: innocent bystanders or new pathogenetic agents?
  • Molecular testing for viral infection demonstrated the presence of cytomegalovirus (CMV) DNA sequences in the adrenal adenoma, but not in the myelolipoma (confirmed by immunohistochemistry).
  • Moreover, the adrenal adenoma was also positive for parvovirus B19, and both adrenal tumor samples were positive for polyomavirus BK (BKV) and adenovirus DNA sequences.
  • The role of these viruses in adrenal tumorigenesis was postulated.
  • [MeSH-major] Adrenal Gland Neoplasms / complications. Adrenocortical Adenoma / pathology. BK Virus / genetics. Cytomegalovirus / genetics. Cytomegalovirus Infections / complications. Polyomavirus Infections / complications

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16864124.001).
  • [ISSN] 1121-760X
  • [Journal-full-title] European journal of histochemistry : EJH
  • [ISO-abbreviation] Eur J Histochem
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Italy
  •  go-up   go-down


30. Meinardi JR, Wolffenbuttel BH, Dullaart RP: Cyclic Cushing's syndrome: a clinical challenge. Eur J Endocrinol; 2007 Sep;157(3):245-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cyclic Cushing's syndrome (CS) is a rare disorder, characterized by repeated episodes of cortisol excess interspersed by periods of normal cortisol secretion.
  • Our review of 65 reported cases demonstrates that cyclic CS originates in 54% of cases from a pituitary corticotroph adenoma, in 26% from an ectopic ACTH-producing tumour and in about 11% from an adrenal tumour, the remainder being unclassified.
  • In cases of suspected ectopic ACTH production, specific biochemical testing for carcinoids or neuroendocrine tumours is required, including measurements of serotonin in platelets and/or urine, chromogranin A and calcitonin.

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17766705.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] WI4X0X7BPJ / Hydrocortisone
  • [Number-of-references] 108
  •  go-up   go-down


31. Tobe M, Ito K, Umeda S, Sato A, Adaniya N, Tanaka Y, Hayakawa M, Asano T: Severe polyuria after the resection of adrenal pheochromocytoma. Int J Urol; 2010 Dec;17(12):1004-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe polyuria after the resection of adrenal pheochromocytoma.
  • A 73-year-old male patient with hypertension and hyperglycemia was referred to our hospital because of a diagnosis regarding his left adrenal tumor.
  • Because the levels of urinary metanephrine and normetanephrine were elevated, and (131) I-MIBG scintigraphy showed intense uptake in the adrenal tumor, the tumor was diagnosed as a pheochromocytoma.
  • Because ADH levels in the tumor fluid were not elevated, the tumor was not an ADH-secreting tumor.
  • Urinary β2-microglobulin was significantly elevated after the operation, thus suggesting that renal tubule dysfunction might also have been involved in the polyuria.
  • However, the mechanism of polyuria after the resection of adrenal pheochromocytoma is not fully understood.
  • Polyuria after the resection of adrenal pheochromocytoma is extremely rare, and the present subject is the second case to date.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenalectomy / adverse effects. Pheochromocytoma / surgery. Polyuria / etiology. Postoperative Complications / etiology

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Japanese Urological Association.
  • (PMID = 20874817.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


32. Hoshiyama F, Hosokawa Y, Kumamoto H, Hayashi Y, Fujimoto K, Hirao Y: [Choriocarcinoma presenting as a spontaneous rupture of an adrenal metastasis: a case report]. Hinyokika Kiyo; 2008 Apr;54(4):281-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Choriocarcinoma presenting as a spontaneous rupture of an adrenal metastasis: a case report].
  • An abdominal enhanced computed tomography (CT) revealed retroperitoneal hemorrhage, leading to life-threatening, and multiple tumors in the liver.
  • These findings strongly indicated a spontaneous rupture of adrenal tumor.
  • An examination during surgery showed a rupture of adrenal tumor.
  • En bloc resection of adrenal gland, tumor, and the kidney was performed.
  • Pathological finding revealed the adrenal tumor was choriocarcinoma.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Choriocarcinoma / pathology. Uterine Neoplasms / pathology

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18516921.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


33. Kvacheniuk AN: [Surgical treatment of adrenocortical cancer: significance of systematic lymphodissection]. Klin Khir; 2008 Mar;(3):34-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adrenalectomy (AE) with en bloc excision of tumor and systematic lymph nodes dissection (paranephral, left-side paraaortal and the right-side paracaval collectors) constitutes the optimal surgical procedure.
  • AE with the tumor en bloc excision without performance of LD may give the same expected efficacy only for I-II stages tumor, when it is impossible to confirm malignancy intraoperatively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18680995.001).
  • [ISSN] 0023-2130
  • [Journal-full-title] Klinichna khirurhiia
  • [ISO-abbreviation] Klin Khir
  • [Language] RUS
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Ukraine
  •  go-up   go-down


34. Ludvigsen L, Toxvaerd A, Mahdi B, Krarup-Hansen A, Bergenfeldt M: Successful resection of an advanced duodenal gastrointestinal stromal tumor after down-staging with imatinib: report of a case. Surg Today; 2007;37(12):1105-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful resection of an advanced duodenal gastrointestinal stromal tumor after down-staging with imatinib: report of a case.
  • The diagnosis of gastrointestinal stromal tumor (GIST) relies on a combination of the following criteria: anatomic location, typical histopathology, and the presence of CD 117-antigen (the tyrosine kinase receptor, c-kit) or CD 34-antigen.
  • We performed Whipple's procedure combined with en bloc resection of the right kidney and adrenal gland.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Duodenal Neoplasms / surgery. Gastrointestinal Stromal Tumors / surgery. Neoplasm Recurrence, Local / surgery. Pancreaticoduodenectomy / methods. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Benzamides. Diagnosis, Differential. Dose-Response Relationship, Drug. Follow-Up Studies. Humans. Imatinib Mesylate. Male. Neoplasm Staging. Positron-Emission Tomography. Protein-Tyrosine Kinases / antagonists & inhibitors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Surgery. 2003 Oct;134(4):656-65; discussion 665-6 [14605627.001]
  • [Cites] Curr Oncol Rep. 2005 Jul;7(4):307-11 [15946591.001]
  • [Cites] Am J Surg. 2003 Dec;186(6):665-9 [14672776.001]
  • [Cites] Am J Surg Pathol. 1983 Sep;7(6):507-19 [6625048.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5795-804 [16110036.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34 [15451219.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1259-69 [9588894.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1316-9 [15793646.001]
  • [Cites] Gastrointest Endosc. 2005 Apr;61(4):625-7 [15812427.001]
  • [Cites] Anticancer Drugs. 2004 Jul;15(6):599-602 [15205603.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):460-4 [12888812.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):566-78 [15781488.001]
  • [Cites] Ann Surg. 1987 Dec;206(6):706-10 [3689007.001]
  • [Cites] Mod Pathol. 2003 Apr;16(4):366-75 [12692202.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):82-7 [9888707.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8118-21 [11719439.001]
  • [Cites] Ann Surg Oncol. 2004 May;11(5):465-75 [15123459.001]
  • [Cites] Ann Surg. 1992 Jan;215(1):68-77 [1731651.001]
  • (PMID = 18030576.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


35. Murphy CG, Scaramuzzi N, Winter DC, Thompson CJ, Broe PJ: Laparoscopic adrenalectomy, an initial experience of fifteen cases. Ir J Med Sci; 2005 Oct-Dec;174(4):39-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Fifteen glands were removed from fifteen patients.
  • The mean gland size was 3.4 cm.
  • CONCLUSION: Our initial experience demonstrates this approach to be the ideal technique for removal of benign adrenal tumours with significant advantages for the patient.
  • [MeSH-major] Adrenal Gland Diseases / surgery. Adrenalectomy / methods. Laparoscopy / methods
  • [MeSH-minor] Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / surgery. Adult. Aged. Female. Follow-Up Studies. Humans. Ireland. Length of Stay. Male. Middle Aged. Pain, Postoperative / diagnosis. Pain, Postoperative / epidemiology. Patient Satisfaction. Postoperative Complications / epidemiology. Prospective Studies. Sampling Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Adrenal Gland Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2000 Nov;24(11):1342-6 [11038204.001]
  • [Cites] World J Surg. 1999 Apr;23(4):389-96 [10030863.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1005-12 [12045858.001]
  • [Cites] Surg Endosc. 2003 Feb;17(2):264-7 [12399875.001]
  • [Cites] Br J Surg. 1997 May;84(5):679-82 [9171764.001]
  • [Cites] ANZ J Surg. 2002 Jul;72(7):467-70 [12123501.001]
  • [Cites] J Urol. 2003 Jan;169(1):32-5 [12478096.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):238-46; discussion 246-7 [9339930.001]
  • [Cites] Arch Surg. 1995 May;130(5):489-92; discussion 492-4 [7748086.001]
  • [Cites] Surg Endosc. 1999 Jan;13(1):35-9 [9869685.001]
  • [Cites] Am J Surg. 1999 Jul;178(1):50-3; discussion 54 [10456703.001]
  • [Cites] J Am Coll Surg. 1996 Jul;183(1):1-10 [8673301.001]
  • [Cites] Surg Endosc. 2002 Sep;16(9):1274-9 [11988798.001]
  • [Cites] N Engl J Med. 1992 Oct 1;327(14):1033 [1387700.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2002 Feb;12(1):1-5 [11905856.001]
  • [Cites] J Urol. 2001 Aug;166(2):429-36 [11458042.001]
  • [Cites] Arch Surg. 1997 Aug;132(8):914-9 [9267279.001]
  • [Cites] Ann Chir. 2002 Sep;127(7):512-9 [12404845.001]
  • (PMID = 16445159.001).
  • [ISSN] 0021-1265
  • [Journal-full-title] Irish journal of medical science
  • [ISO-abbreviation] Ir J Med Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


36. Nomura K, Kimura H, Shimizu S, Kodama H, Okamoto T, Obara T, Takano K: Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy. J Clin Endocrinol Metab; 2009 Aug;94(8):2850-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-five patients had undergone excision of their primary tumors.
  • RESULTS: The survival curve of the 32 patients declined continuously and linearly to at least 20 yr after the diagnosis of pheochromocytoma.
  • In the 25 patients whose primary tumor was excised, patients who already had metastases at the time of pheochromocytoma diagnosis had better survival than those whose metastases were found later.
  • The survival rate after diagnosis of metastasis was worse in the CVD group than in controls.
  • When the effects of CVD were examined after stratifying several factors, female gender and adrenal origin of tumor were found to be negative prognostic factors for CVD chemotherapy.
  • CVD chemotherapy was not shown to extend survival, especially for women and patients with adrenal gland-derived primary tumors.
  • [MeSH-major] Adrenal Gland Neoplasms / mortality. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pheochromocytoma / mortality
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Survival Rate. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19470630.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


37. Cavlan D, Bharwani N, Grossman A: Androgen- and estrogen-secreting adrenal cancers. Semin Oncol; 2010 Dec;37(6):638-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Androgen- and estrogen-secreting adrenal cancers.
  • Androgen-secreting adrenal cancers are extremely rare malignancies, accounting for only a tiny proportion of the total number of women presenting with signs of androgen excess.
  • Estrogen-secreting adrenal cancers are rarer still.
  • Understanding how these tumors work benefits from an appreciation of adrenal steroid biosynthesis, as it is said that secretion in cancers is an anarchic version of normal adrenal function.
  • When an adrenal tumor is found to secrete androgens or estrogens to excess, it can be difficult to confirm that it is a cancer, as there is significant overlap in the secretory patterns and imaging appearances of benign and malignant disease.
  • The most reliable indicator of malignancy in these tumors remains the presence of metastases.
  • [MeSH-major] Adrenal Gland Neoplasms / secretion. Androgens / secretion. Estrogens / secretion
  • [MeSH-minor] Adrenalectomy. Adrenocortical Carcinoma / diagnosis. Adrenocortical Carcinoma / secretion. Adrenocortical Carcinoma / therapy. Adult. Algorithms. Antineoplastic Agents, Hormonal / therapeutic use. Child. Diagnostic Imaging / methods. Female. Humans. Mitotane / therapeutic use. Prognosis. Virilism / etiology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21167382.001).
  • [ISSN] 1532-8708
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Antineoplastic Agents, Hormonal; 0 / Estrogens; 78E4J5IB5J / Mitotane
  •  go-up   go-down


38. Bandi G, Wen CC, Moon TD, Nakada SY: Single center preliminary experience with hand-assisted laparoscopic resection of isolated renal cell carcinoma fossa recurrences. Urology; 2008 Mar;71(3):495-9; discussion 499-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single center preliminary experience with hand-assisted laparoscopic resection of isolated renal cell carcinoma fossa recurrences.
  • OBJECTIVES: Solitary metastasis to the renal fossa after radical nephrectomy for renal cell carcinoma is uncommon.
  • We report the first series on hand-assisted laparoscopic excision for renal cell carcinoma fossa recurrences.
  • METHODS: We performed a retrospective review of patients who underwent hand-assisted laparoscopic excision of renal cell carcinoma fossa recurrence.
  • Patients with distant metastasis or local lymph node or adrenal metastasis were excluded from analysis.
  • We collected data on patient and tumor characteristics, nephrectomy and fossa mass excision procedures, and postoperative outcomes.
  • RESULTS: Between 2001 and 2007, 5 patients underwent laparoscopic resection of a renal fossa recurrence.
  • Mean time to recurrence after radical nephrectomy was 23 months (range, 5 to 46 months) and mean size of the renal fossa mass was 6 cm (range, 4.2 to 9.5 cm).
  • With mean follow-up of 43 months, the cancer-specific and disease-free survival rates were 60% and 20%, respectively.
  • Of the 4 patients who underwent complete resection, 2 died from metastatic disease at 13 and 56 months, 1 continues to have progressive metastatic disease at 69 months, and 1 remains free of any clinical evidence of metastatic disease or recurrence at 37 months.
  • One patient who underwent incomplete resection as a result of inferior vena cava invasion continues to have progressive local and distant metastatic disease at 40-month follow-up.
  • CONCLUSIONS: Hand-assisted laparoscopic excision of renal fossa recurrence after radical nephrectomy appears to be safe and effective for carefully selected patients.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Laparoscopy / methods. Neoplasm Recurrence, Local / surgery. Nephrectomy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342195.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Sikora MJ, Cordero KE, Larios JM, Johnson MD, Lippman ME, Rae JM: The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance. Breast Cancer Res Treat; 2009 May;115(2):289-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aromatase inhibitors (AIs) are used to treat estrogen receptor-positive (ER+) breast tumors in post-menopausal women, and function by blocking the conversion of adrenal androgens to estrogens by the enzyme CYP19 aromatase.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 2004 May;85(2):151-9 [15111773.001]
  • [Cites] Breast Cancer Res Treat. 2004 Jan;83(2):99-107 [14997040.001]
  • [Cites] Cancer Res. 1976 Dec;36(12):4610-8 [1000506.001]
  • [Cites] Steroids. 1979 Jun;33(6):675-92 [37613.001]
  • [Cites] J Steroid Biochem. 1986 Nov;25(5B):749-57 [2433505.001]
  • [Cites] J Biol Chem. 1987 Sep 5;262(25):12293-7 [3624260.001]
  • [Cites] Cancer Res. 1993 Jan 15;53(2):266-70 [8417819.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Aug;77(2):324-31 [8345035.001]
  • [Cites] Mol Cell Endocrinol. 1994 Aug;104(1):103-11 [7821701.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2132-8 [7697604.001]
  • [Cites] J Steroid Biochem Mol Biol. 1995 May;52(5):459-67 [7748811.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Oct;80(10):2918-25 [7559875.001]
  • [Cites] Endocrinology. 1997 Mar;138(3):863-70 [9048584.001]
  • [Cites] Breast Cancer Res Treat. 1997 May;44(1):57-64 [9164678.001]
  • [Cites] Endocrinology. 1998 Oct;139(10):4164-74 [9751496.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4864-9 [10519397.001]
  • [Cites] Endocrinology. 2005 Jan;146(1):147-55 [15471969.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):619-29 [15545664.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2814-9 [15710898.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Jan;93(1):25-34 [15748829.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5445-53 [15958594.001]
  • [Cites] Breast Cancer Res Treat. 2005 Jul;92(2):141-9 [15986123.001]
  • [Cites] J Steroid Biochem Mol Biol. 2006 Feb;98(2-3):133-8 [16386416.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7775-82 [16885381.001]
  • [Cites] Steroids. 2007 Jul;72(8):666-71 [17588628.001]
  • [Cites] Prostate. 2007 Sep 15;67(13):1439-46 [17639508.001]
  • [Cites] Steroids. 2007 Dec;72(14):914-22 [17854852.001]
  • [Cites] FEBS J. 2008 Apr;275(8):1778-89 [18331353.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 22;98(11):6330-5 [11371645.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13589-94 [12370428.001]
  • [Cites] Nature. 1975 Nov 27;258(5533):339-41 [172794.001]
  • (PMID = 18521740.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / T-32 GM007767; United States / NIGMS NIH HHS / GM / T32 GM007767; United States / NIGMS NIH HHS / GM / GM007767-32; United States / NCATS NIH HHS / TR / UL1 TR000101; United States / NIGMS NIH HHS / GM / U-01 GM61373; United States / NIGMS NIH HHS / GM / GM061373-09; United States / NIGMS NIH HHS / GM / U01 GM061373-09; United States / NIGMS NIH HHS / GM / T32 GM007767-32; United States / NIGMS NIH HHS / GM / U01 GM061373
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Androgens; 0 / Aromatase Inhibitors; 0 / Estrogen Receptor Modulators; 0 / Estrogen Receptor alpha; 25126-76-5 / Androstane-3,17-diol
  • [Other-IDs] NLM/ NIHMS126984; NLM/ PMC2728015
  •  go-up   go-down


40. Thorin-Savouré A, Tissier-Rible F, Guignat L, Pellerin A, Bertagna X, Bertherat J, Lefebvre H: Collision/composite tumors of the adrenal gland: a pitfall of scintigraphy imaging and hormone assays in the detection of adrenal metastasis. J Clin Endocrinol Metab; 2005 Aug;90(8):4924-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision/composite tumors of the adrenal gland: a pitfall of scintigraphy imaging and hormone assays in the detection of adrenal metastasis.
  • CONTEXT: In patients with a history of extraadrenal tumor, incidental discovery of an adrenal mass necessitates excluding the possibility of metastatic malignancy.
  • Detection of the malignant tissue is a difficult challenge when metastasis occurs in an adrenal adenoma, forming a collision/composite tumor.
  • OBJECTIVE, DESIGN, AND SETTING: We report two patients with adrenal collision/composite tumors referred to two French university hospitals.
  • PATIENTS AND RESULTS: Two patients with histories of mammary and sigmoid carcinomas, respectively, presented with adrenal mass discovered 8 and 3 yr after surgical removal of the primary tumor.
  • In the two cases, computerized tomographic scan showed that the adrenal tumor contained two components with low and high attenuation values, respectively.
  • Uptake of iodocholesterol by the adrenal tumor in case 1 and elevated plasma ACTH-stimulated 17-hydroxyprogesterone values in case 2 strongly argued for the diagnosis of primary adrenocortical tumors.
  • Enlargement of the adrenal mass during follow-up in case 1 and association of the adrenal lesion with a hepatic mass in case 2 led to adrenalectomy.
  • In both cases, histological examination of the tumor demonstrated the presence of metastatic carcinoma tissue in an adrenocortical adenoma, allowing classification of the neoplasia as a collision/composite tumor.
  • CONCLUSION: These observations show that collision/composite tumors of the adrenal gland formed by carcinoma metastasis in benign adenomas are a pitfall of iodocholesterol scintigraphy and/or plasma steroid assays to exclude the diagnosis of adrenal metastasis.
  • Conversely, computerized tomographic scan is a useful tool for the distinction between the benign and malignant tissues in adrenal collision/composite tumors.
  • [MeSH-major] Adenoma / pathology. Adenoma / radionuclide imaging. Adrenal Gland Neoplasms / radionuclide imaging. Adrenal Gland Neoplasms / secondary. Breast Neoplasms / pathology. Sigmoid Neoplasms / pathology
  • [MeSH-minor] 19-Iodocholesterol. Adrenocorticotropic Hormone / blood. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15914530.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 30461-91-7 / 19-Iodocholesterol; 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


41. Miyagawa-Hayashino A, Sonobe M, Kubo T, Yoshizawa A, Date H, Manabe T: Non-specific interstitial pneumonia as a manifestation of graft-versus-host disease following pediatric allogeneic hematopoietic stem cell transplantation. Pathol Int; 2010 Feb;60(2):137-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-specific interstitial pneumonia as a manifestation of graft-versus-host disease following pediatric allogeneic hematopoietic stem cell transplantation.
  • Bronchiolitis obliterans (BO) is generally believed to be a marker of pulmonary manifestation of graft-versus-host disease (GVHD) in patients who have undergone bone marrow transplantation for hematological malignancy.
  • Pulmonary manifestations reported as GVHD (other than BO) include lymphocytic bronchiolitis with cellular interstitial pneumonia, lymphoid interstitial pneumonia, veno-occlusive disease, and diffuse alveolar damage.
  • Reported herein is a fibrosing non-specific interstitial pneumonia (NSIP) pattern together with BO in both lungs in an 8-year-old girl following a second allogeneic hematopoietic stem cell transplantation for relapsed neuroblastoma of adrenal origin.
  • [MeSH-major] Graft vs Host Disease / complications. Hematopoietic Stem Cell Transplantation / adverse effects. Lung Diseases, Interstitial / etiology. Lung Diseases, Interstitial / pathology
  • [MeSH-minor] Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / therapy. Bronchiolitis Obliterans / etiology. Bronchiolitis Obliterans / pathology. Child. Female. Humans. Lung Transplantation. Neoplasm Recurrence, Local / therapy. Neuroblastoma / pathology. Neuroblastoma / therapy. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Interstitial Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20398200.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


42. Brauckhoff M, Dralle H: [Recurrent operations on the adrenal glands]. Chirurg; 2005 Mar;76(3):227-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrent operations on the adrenal glands].
  • Repeat adrenalectomy may be required due to ipsilateral recurrence of benign or malignant adrenal tumors after previous total or subtotal adrenalectomy.
  • Even for multivisceral resection in patients with adrenocortical carcinoma, complete resection of local recurrent tumor offers results similar to those of primary resection (5-year survival 40-60%).
  • In contrast, since no benefit on long-term survival has been shown so far by tumor debulking, palliative tumor resection should only be performed individually for control of severe endocrine symptoms.
  • The effect of endoscopic adrenalectomy in patients with large tumors (>5 cm) or suspected malignancy has still not been well examined.
  • In any case, during open or endoscopic approach, tumor spillage must be avoided to prevent local tumor cell implantation.
  • Following subtotal adrenalectomy, the risk of ipsilateral recurrence correlates with disease, follow-up, localization, size of the adrenal remnant, and, in case of familial pheochromocytoma, probably with genotype.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods. Adrenocortical Carcinoma / surgery. Neoplasm Recurrence, Local / surgery. Pheochromocytoma / surgery
  • [MeSH-minor] 3-Iodobenzylguanidine / therapeutic use. Adult. Antineoplastic Agents, Hormonal / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymph Node Excision. Male. Middle Aged. Mitotane / therapeutic use. Octreotide / therapeutic use. Palliative Care. Paraneoplastic Endocrine Syndromes / diagnosis. Paraneoplastic Endocrine Syndromes / mortality. Paraneoplastic Endocrine Syndromes / surgery. Radiotherapy, Adjuvant. Reoperation

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endourol. 1999 Mar;13(2):99-104; discussion 104-6 [10213103.001]
  • [Cites] Arch Surg. 2001 May;136(5):543-9 [11343545.001]
  • [Cites] Surgery. 2001 Dec;130(6):1072-7 [11742341.001]
  • [Cites] Ann Thorac Surg. 1996 Jan;61(1):222-4 [8561564.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1043-7 [12045859.001]
  • [Cites] Eur J Surg. 1999 May;165(5):431-5 [10391158.001]
  • [Cites] World J Surg. 1990 May-Jun;14(3):325-9 [1973322.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1347-52 [11038205.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1323-9 [15517476.001]
  • [Cites] World J Surg. 2000 Jan;24(1):108-13 [10594213.001]
  • [Cites] Surgery. 1992 Dec;112(6):963-70; discussion 970-1 [1455321.001]
  • [Cites] Eur J Endocrinol. 2004 Jun;150(6):789-92 [15191348.001]
  • [Cites] Surgery. 2003 Dec;134(6):1020-7; discussion 1027-8 [14668736.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1005-12 [12045858.001]
  • [Cites] World J Surg. 1998 Jun;22(6):621-6; discussion 626-7 [9597938.001]
  • [Cites] N Engl J Med. 1977 Jun 2;296(22):1269-71 [859517.001]
  • [Cites] Endocr J. 2002 Apr;49(2):227-9 [12081243.001]
  • [Cites] Surgery. 1995 Dec;118(6):1090-8 [7491528.001]
  • [Cites] Urology. 1999 Apr;53(4):679-83 [10197840.001]
  • [Cites] Horm Res. 2002;57(5-6):197-9 [12053093.001]
  • [Cites] World J Surg. 2001 Jul;25(7):914-26 [11572033.001]
  • [Cites] Surg Today. 2004;34(3):251-5 [14999539.001]
  • [Cites] Surgery. 1985 Jan;97(1):16-20 [3966225.001]
  • [Cites] Surgery. 2000 Dec;128(6):1007-11;discussion 1011-2 [11114636.001]
  • [Cites] Endocr Rev. 2001 Feb;22(1):75-110 [11159817.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):719-26 [10622498.001]
  • [Cites] Chirurg. 2003 May;74(5):473-7 [12748796.001]
  • [Cites] World J Surg. 1990 May-Jun;14(3):330-4 [2368435.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):5-7 [10634355.001]
  • [Cites] J Am Coll Surg. 2004 Apr;198(4):525-34; discussion 534-5 [15051000.001]
  • [Cites] J Pediatr Surg. 1993 Oct;28(10):1248-51; discussion 1251-2 [8263682.001]
  • [Cites] J Intern Med. 1995 Oct;238(4):363-7 [7595173.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Nov;69(5):1078-81 [2793991.001]
  • [Cites] Eur J Surg. 1999 Jun;165(6):535-8 [10433135.001]
  • [Cites] Surgery. 2003 Dec;134(6):956-62; discussion 962-3 [14668728.001]
  • [Cites] Surgery. 1996 Dec;120(6):1064-70; discussion 1070-1 [8957496.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Jan;46(1):39-44 [9059556.001]
  • [Cites] World J Surg. 1992 Jul-Aug;16(4):753-8 [1413845.001]
  • [Cites] Surgery. 2002 Dec;132(6):1008-11; discussion 1012 [12490848.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2004 Aug;14(4):234-5 [15345163.001]
  • [Cites] J Urol. 1997 Jun;157(6):2239 [9146626.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Dec;87(12):5367-84 [12466322.001]
  • [Cites] J Urol. 1999 Feb;161(2):395-8 [9915410.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4083-7 [12970267.001]
  • [Cites] J Urol. 2000 Jul;164(1):14-7 [10840414.001]
  • [Cites] Arch Surg. 2002 Jun;137(6):682-8; discussion 688-9 [12049539.001]
  • [Cites] World J Surg. 1982 Jul;6(4):397-402 [7123976.001]
  • [Cites] World J Surg. 1984 Aug;8(4):612-21 [6148811.001]
  • [Cites] Surgery. 1997 Dec;122(6):1068-73; discussion 1073-4 [9426421.001]
  • [Cites] ANZ J Surg. 2003 Aug;73(8):664-6 [12887546.001]
  • [Cites] Horm Res. 1999;52(2):97-100 [10681640.001]
  • [Cites] Eur Urol. 2000 Sep;38(3):344-8 [10940711.001]
  • [Cites] Minn Med. 1974 Dec;57(12):951-2 [4424014.001]
  • [Cites] Eur J Endocrinol. 2004 Jul;151(1):15-27 [15248818.001]
  • [Cites] J Endourol. 2002 Apr;16(3):171-4 [12028627.001]
  • [Cites] Chirurg. 1989 Apr;60(4):266-71; discussion 271-2 [2566455.001]
  • [Cites] Arch Surg. 1974 Apr;108(4):450-4 [4815920.001]
  • [Cites] Front Horm Res. 2004;31:155-62 [14674310.001]
  • [Cites] Surgery. 1997 Dec;122(6):1212-8 [9426440.001]
  • [Cites] Br J Surg. 1999 Jan;86(1):94-7 [10027369.001]
  • [Cites] J Urol. 1998 Aug;160(2):330-4 [9679871.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Mar;60(3):273-87 [15008991.001]
  • [Cites] Surgery. 1983 Dec;94(6):938-40 [6648808.001]
  • [Cites] Henry Ford Hosp Med J. 1987;35(2-3):127-8 [2891644.001]
  • (PMID = 15739057.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 35MRW7B4AD / 3-Iodobenzylguanidine; 78E4J5IB5J / Mitotane; RWM8CCW8GP / Octreotide
  • [Number-of-references] 45
  •  go-up   go-down


43. van Nederveen FH, Perren A, Dannenberg H, Petri BJ, Dinjens WN, Komminoth P, de Krijger RR: PTEN gene loss, but not mutation, in benign and malignant phaeochromocytomas. J Pathol; 2006 Jun;209(2):274-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The gene is thought to be one of the most frequently mutated tumour suppressor genes and inactivation of PTEN is associated with disease progression and angiogenesis.
  • This study therefore evaluated whether inactivation of PTEN may be involved in the tumourigenesis of PCC in man and whether PTEN abnormalities may help to define the malignant potential of these tumours.
  • Tumour and germline DNA was analysed from 31 patients with apparently sporadic PCC, including 14 clinically benign and 17 malignant tumours, for loss of the PTEN gene locus, mutations in the PTEN gene, and for PTEN protein expression by immunohistochemistry.
  • Loss of heterozygosity (LOH) analysis showed loss of PTEN in four malignant tumours (40%) and in one benign tumour (14%).
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Genes, Tumor Suppressor / physiology. Neoplasm Proteins / genetics. PTEN Phosphohydrolase / genetics. Pheochromocytoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. DNA Mutational Analysis / methods. DNA, Neoplasm / genetics. Female. Gene Silencing / physiology. Humans. Immunohistochemistry / methods. Loss of Heterozygosity / genetics. Male. Middle Aged. Polymorphism, Single-Stranded Conformational

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Pathological Society of Great Britain and Ireland.
  • (PMID = 16538614.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


44. Lo WK, vansonnenberg E, Shankar S, Morrison PR, Silverman SG, Tuncali K, Rabin M: Percutaneous CT-guided radiofrequency ablation of symptomatic bilateral adrenal metastases in a single session. J Vasc Interv Radiol; 2006 Jan;17(1):175-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous CT-guided radiofrequency ablation of symptomatic bilateral adrenal metastases in a single session.
  • Percutaneous computed tomography (CT)-guided radiofrequency (RF) ablation has been used in the palliative treatment of symptomatic bilateral adrenal tumors, often with each tumor addressed separately over the course of multiple treatment sessions.
  • In the present case, a 71-year-old man with a diagnosis of lung cancer and painful bilateral metastases to the adrenal glands underwent percutaneous CT-guided RF thermal ablation of both adrenal masses in a single session (left adrenal mass, 4.7 cm; right adrenal mass, 4.3 cm), without occurrence of blood pressure instability or other acute complications.
  • [MeSH-major] Adenocarcinoma / surgery. Adrenal Gland Neoplasms / surgery. Catheter Ablation
  • [MeSH-minor] Aged. Humans. Lung Neoplasms / pathology. Male. Pain / etiology. Pain / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16415149.001).
  • [ISSN] 1051-0443
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Przybylik-Mazurek E, Buziak-Bereza M, Fedorowicz A, Kuźniarz-Rymarz S, Stochmal E, Hubalewska-Dydejczyk A: [Retrospective hormonal analysis of incidentally discovered and operated adrenal tumors for subclinical Cushing's syndrome]. Przegl Lek; 2010;67(12):1270-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Retrospective hormonal analysis of incidentally discovered and operated adrenal tumors for subclinical Cushing's syndrome].
  • In the last twenty years the introduction of new imaging techniques has caused increasing incidence of accidental detection of adrenal tumors, which are usually mild and in most cases are hormonally inactive adenomas.
  • Among hormonal disorders in patients with adrenal incidentalomas the hypercortisolism is often described, which, if not treated properly, leads to multiple organ complications, and further to the patient's death.
  • The aim of the study was the retrospective analysis of the group of patients with adrenal incidentaloma, verified by histopathology for assessment of subclinical Cushing's syndrome.
  • Among the group of 225 patients: 62 men and 163 women with incidentally detected adrenal tumors in age from 19 to 81 years diagnosed and treated in the Department of Clinical Endocrinology, University Hospital in Krakow, 59 patients was sent to surgery: 15 men and 42 women.
  • Group A consisted of patients with adrenal cortical adenoma: 38 people (11 men and 27 women).
  • In group B there were people with so-called other hormonal inactive adrenal tumors - 17 people (4 men and 13 women).
  • A detailed analysis of the clinical signs, meticulously carried out and repeated hormonal diagnosis with the use of functional tests should be focused on the detection of subclinical hormonal disorders, which is crucial in preventing organ damage and making a decision of the right treatment of the patient, which is surgical.
  • [MeSH-major] Adrenal Gland Neoplasms / blood. Adrenal Gland Neoplasms / surgery. Hydrocortisone / blood

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21591352.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] WI4X0X7BPJ / Hydrocortisone; Adrenal incidentaloma
  •  go-up   go-down


46. Nguyen CT, Campbell SC: Staging of renal cell carcinoma: past, present, and future. Clin Genitourin Cancer; 2006 Dec;5(3):190-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging of renal cell carcinoma: past, present, and future.
  • Tumor stage, which describes the anatomic extent of disease, is a powerful determinant of prognosis and survival for patients with renal cell carcinoma (RCC).
  • Stratification of patients based on prognostic outcomes derived from staging systems facilitates therapeutic decision-making, disease surveillance, and clinical research.
  • The most recent revisions of the TNM system for RCC introduced in 1997 and 2002 further subdivided organ-confined tumors, reclassified tumors with venous involvement, and clarified the staging of tumors that invade the perisinus fat.
  • Nevertheless, additional modifications have been proposed that would alter the subclassification of organ-confined disease, integrate various levels of venous involvement with other aspects of local tumor aggressiveness, and upgrade the classification of adrenal involvement.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Neoplasm Staging / trends
  • [MeSH-minor] Biomarkers, Tumor / analysis. Forecasting. History, 20th Century. History, 21st Century. Humans. Prognosis. Renal Veins / physiopathology. Venous Thrombosis / physiopathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17239272.001).
  • [ISSN] 1558-7673
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 94
  •  go-up   go-down


47. Loriot Y, Ferte C, Gomez-Roca C, Moldovan C, Bahleda R, Wislez M, Cadranel J, Soria JC: Pemetrexed-induced pneumonitis: a case report. Clin Lung Cancer; 2009 Sep;10(5):364-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pemetrexed is a structurally novel antifolate agent approved in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma who have unresectable disease and for the therapy of previously treated patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) as a single agent or in association with cisplatin as a first-line treatment in patients with nonsquamous histology.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Drug Hypersensitivity / diagnosis. Lung / drug effects. Lung Neoplasms / drug therapy. Pneumonia / diagnosis. Solitary Pulmonary Nodule / drug therapy
  • [MeSH-minor] Adrenal Cortex Hormones / administration & dosage. Aged. Anti-Infective Agents / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Ciprofloxacin / administration & dosage. Cisplatin / administration & dosage. Cisplatin / adverse effects. Drug Therapy, Combination. Dyspnea. Erythema. Glutamates / administration & dosage. Glutamates / adverse effects. Guanine / administration & dosage. Guanine / adverse effects. Guanine / analogs & derivatives. Humans. Male. Neoplasm Recurrence, Local. Paclitaxel / administration & dosage. Pemetrexed. Pulmonary Fibrosis. Recovery of Function

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pneumonia.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. GUANINE .
  • Hazardous Substances Data Bank. CIPROFLOXACIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19808196.001).
  • [ISSN] 1938-0690
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anti-Infective Agents; 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5E8K9I0O4U / Ciprofloxacin; 5Z93L87A1R / Guanine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


48. Eisen T, Thatcher N, Leyvraz S, Miller WH Jr, Couture F, Lorigan P, Lüthi F, Small D, Tanovic A, O'Brien M: Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. Lung Cancer; 2009 Apr;64(1):60-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment lasted until disease progression, unacceptable toxicity, patient refusal or treatment delay for >2 weeks.
  • Objective response rate (primary efficacy endpoint) was evaluated according to response evaluation criteria in solid tumors (RECIST).
  • The rate of stable disease (SD) lasting for at least 6 months and time-to-event variables were secondary endpoints of efficacy.
  • RESULTS: Twenty pretreated SCLC patients (median age, 60 years) with extensive (n = 13) or limited-stage disease (n = 7) received a total of 24 treatment cycles (median, one cycle per patient; range, 1-2).
  • Objective tumor responses were not observed and only one of the 17 evaluable patients had SD.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Depsipeptides / administration & dosage. Lung Neoplasms / drug therapy. Small Cell Lung Carcinoma / drug therapy
  • [MeSH-minor] Adrenal Gland Neoplasms / drug therapy. Adrenal Gland Neoplasms / secondary. Adult. Aged. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Female. Humans. Infusions, Intravenous. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Prognosis. Salvage Therapy. Skin Neoplasms / drug therapy. Skin Neoplasms / secondary. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18692272.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Depsipeptides; Y76ID234HW / aplidine
  •  go-up   go-down


49. Kastelan D, Dusek T, Aganović I, Stern-Padovan R, Kuzmanić D, Kastelan Z, Knezević N, Crncević-Orlić Z, Kraljević I, Dzubur F, Pavlić-Renar I, Giljević Z, Jelcić J, Baretić M, Skorić T, Korsić M: [Management of adrenal incidentaloma: the position statement of the Croatian referral center for adrenal gland disorders]. Lijec Vjesn; 2010 Mar-Apr;132(3-4):71-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of adrenal incidentaloma: the position statement of the Croatian referral center for adrenal gland disorders].
  • Adrenal incidentalomas are tumours of adrenal glands discovered during diagnostic workup for other clinical condition unrelated to adrenal glands.
  • Improvement in imaging techniques and their widespread use in everyday practice have increased detection of adrenal incidentalomas making their management one of the most important challenges of modern endocrinology.
  • Based on the relevant medical literature and guidelines of other international societies a panel of Croatian leading experts in adrenal gland disorders provide practical recommendations for the diagnostics and treatment of adrenal incidentaloma.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis
  • [MeSH-minor] Cushing Syndrome / diagnosis. Humans. Incidental Findings

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20540431.001).
  • [ISSN] 0024-3477
  • [Journal-full-title] Lijec̆nic̆ki vjesnik
  • [ISO-abbreviation] Lijec Vjesn
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Croatia
  • [Number-of-references] 35
  •  go-up   go-down


50. Murphy JJ, Tawfeeq M, Chang B, Nadel H: Early experience with PET/CT scan in the evaluation of pediatric abdominal neoplasms. J Pediatr Surg; 2008 Dec;43(12):2186-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early experience with PET/CT scan in the evaluation of pediatric abdominal neoplasms.
  • It has the potential to be a valuable tool in the evaluation of pediatric abdominal tumors.
  • METHODS: Children who underwent PET/CT scan in the workup for abdominal neoplasms between July 2005 and January 2008 were identified.
  • These included Burkitt's lymphoma (8), neuroblastoma (7), rhabdomyosarcoma (6), ovarian tumor (3), Wilms' tumor (2), hepatocellular carcinoma (2), paraganglioma (1), germ cell tumor (1), undifferentiated sarcoma (1), renal primitive neuroectodermal tumor (1), gastrointestinal stromal tumor (1), adrenocortical carcinoma (1), inflammatory pseudotumor (1), and adrenal adenoma (1).
  • All neoplasms were fluorodeoxyglucose (FDG) were avid.
  • These include (1) preoperative staging, (2) selection of appropriate site for biopsy, (3) identification of occult metastatic disease, (4) follow-up for residual or recurrent disease, and (5) assessment of response to chemotherapy.
  • [MeSH-major] Abdominal Neoplasms / radiography. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Drug Monitoring. Female. Fluorodeoxyglucose F18 / pharmacokinetics. Humans. Male. Neoplasm Staging / methods. Neoplasm, Residual. Postoperative Care / methods. Preoperative Care / methods. Radiopharmaceuticals / pharmacokinetics. Retrospective Studies

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19040932.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


51. Hill KE, Scott-Moncrieff JC, Koshko MA, Glickman LT, Glickman NW, Nelson RW, Blevins WE, Oliver JW: Secretion of sex hormones in dogs with adrenal dysfunction. J Am Vet Med Assoc; 2005 Feb 15;226(4):556-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secretion of sex hormones in dogs with adrenal dysfunction.
  • OBJECTIVE: To evaluate adrenal sex hormone concentrations in response to ACTH stimulation in healthy dogs, dogs with adrenal tumors, and dogs with pituitary-dependent hyperadrenocorticism (PDH).
  • ANIMALS: 11 healthy control dogs, 9 dogs with adrenal-dependent hyperadrenocorticism (adenocarcinoma [ACA] or other tumor); 11 dogs with PDH, and 6 dogs with noncortisol-secreting adrenal tumors (ATs).
  • CONCLUSIONS AND CLINICAL RELEVANCE: Dogs with ACA secrete increased concentrations of adrenal sex hormones, compared with dogs with PDH, noncortisol-secreting ATs, and healthy dogs.
  • [MeSH-major] Adrenal Cortex Hormones / secretion. Adrenal Cortex Neoplasms / veterinary. Adrenocortical Hyperfunction / veterinary. Adrenocorticotropic Hormone / secretion. Dog Diseases / metabolism

  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • SciCrunch. OMIA - Online Mendelian Inheritance in Animals: Data: Gene Expression .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15742696.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 3XMK78S47O / Testosterone; 4G7DS2Q64Y / Progesterone; 7S5I7G3JQL / Dexamethasone; 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


52. Libè R, Groussin L, Tissier F, Elie C, René-Corail F, Fratticci A, Jullian E, Beck-Peccoz P, Bertagna X, Gicquel C, Bertherat J: Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin Cancer Res; 2007 Feb 1;13(3):844-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor suppressor gene TP53 is located at 17p13.
  • The aim of the study was to determine the frequency of TP53 somatic inactivating mutations in adrenocortical tumors with 17p13 LOH and their clinico-biological correlations.
  • EXPERIMENTAL DESIGN: TP53 somatic mutations, intragenic LOH (VNTR1 marker), and p53 overexpression were studied in 36 adrenocortical tumors with 17p13 LOH determined by Southern blot.
  • RESULTS: TP53 mutations were detected in 33% of the tumors, and VNTR1 LOH was present in 44% of the cases and did not always correlate with the presence of a TP53 mutation.
  • Only the TP53-mutant tumors exhibit a strong nuclear immunoreactivity.
  • TP53-mutant tumors were significantly larger than wild-type TP53 tumors (median tumor weight: 640 versus 185 g; P=0.02), were associated with a more advanced stage of tumor progression (MacFarlane stage IV; P=0.01), and had a shorter disease-free survival (P=0.03).
  • CONCLUSIONS: The finding that only a minority of adrenocortical tumors with 17p13 LOH had either a VNTR1 LOH or a TP53 mutation indicates that TP53 might not be the only or major tumor suppressor gene at 17p13 involved in adrenocortical cancer progression.
  • TP53 might be only one of them, and its alteration by the occurrence of inactivating mutation is associated with the development of more aggressive tumors.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Chromosomes, Human, Pair 17. Genes, p53. Loss of Heterozygosity. Minisatellite Repeats / genetics. Mutation
  • [MeSH-minor] Adult. Alleles. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. RNA, Neoplasm / chemistry

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17289876.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Neoplasm
  •  go-up   go-down


53. Iskandar ZA, Al-Joudi FS: Expression of survivin in fetal and adult normal tissues of rat. Malays J Pathol; 2006 Dec;28(2):101-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This serum demonstrated intense positive survivin staining in adult kidney, ovary and oviduct, and a variable expression in different fetal organs, with particularly intense expression detected in the adrenal gland, liver, stomach, small intestine, colon, kidney and skin.
  • [MeSH-minor] Amino Acid Sequence. Animals. Cytoplasm / metabolism. Female. Fluorescent Antibody Technique, Indirect. Immunoenzyme Techniques. Inhibitor of Apoptosis Proteins. Male. Molecular Sequence Data. Neoplasm Proteins / chemistry. Pregnancy. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Fetal Health and Development.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376799.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Birc5 protein, rat; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


54. Kondo K, Chijiiwa K, Nagano M, Hamasuna R, Yamashita A, Marutsuka K, Takahashi N, Akiyama Y: Two-stage operation for hepatocellular carcinoma with synchronous bilateral adrenal gland metastasis. J Hepatobiliary Pancreat Surg; 2008;15(2):232-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two-stage operation for hepatocellular carcinoma with synchronous bilateral adrenal gland metastasis.
  • Hepatocellular carcinoma (HCC) frequently metastasizes to the adrenal glands.
  • The surgical strategy for HCC associated with bilateral adrenal gland metastasis is complicated because of the possibility of both postoperative hepatic failure and adrenal insufficiency.
  • We herein report a patient with HCC with synchronous bilateral adrenal gland metastasis that was treated successfully with a two-stage operation.
  • A 58-year-old man with HCC (12 cm in diameter) in the right lobe of the liver and bilateral adrenal gland tumors (right, 4 cm in diameter; left, 5 cm in diameter) was admitted to our hospital.
  • Two-stage surgery is a safe treatment option for giant HCC with synchronous bilateral adrenal gland metastasis.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392722.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


55. Nawar R, Aron D: Adrenal incidentalomas -- a continuing management dilemma. Endocr Relat Cancer; 2005 Sep;12(3):585-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal incidentalomas -- a continuing management dilemma.
  • Adrenal incidentalomas (AI), adrenal tumors detected through an imaging procedure done for reasons unrelated to adrenal dysfunction, is becoming a common clinical problem with the more frequent utilization of different imaging techniques.
  • Most such tumors are benign and hormonally inactive.
  • The benefit of making a diagnosis of a clinically significant AI must be considered in the context of the patient's overall condition and preferences.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / physiopathology. Incidental Findings
  • [MeSH-minor] Adrenal Gland Diseases / diagnosis. Adrenal Gland Diseases / etiology. Humans. National Institutes of Health (U.S.). Pheochromocytoma / diagnosis. United States

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16172193.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 99
  •  go-up   go-down


56. Huang CY, Chung SD, Wang SM, Liao CH, Lai MK, Huang KH, Pu YS, Chueh SC, Yu HJ: An audit of nephroureterectomy for upper tract urothelial carcinoma. Eur J Surg Oncol; 2009 Dec;35(12):1333-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: No patient had adrenal metastasis among the 40 adrenalectomized patients.
  • Adrenal-sparing nephroureterectomy seems justified for clinically localized upper tract urothelial carcinoma.
  • [MeSH-major] Adrenalectomy / methods. Nephrectomy / methods. Ureter / surgery. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Female. Humans. Male. Medical Audit. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581070.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Mobine HR, Baker AB, Wang L, Wakimoto H, Jacobsen KC, Seidman CE, Seidman JG, Edelman ER: Pheochromocytoma-induced cardiomyopathy is modulated by the synergistic effects of cell-secreted factors. Circ Heart Fail; 2009 Mar;2(2):121-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pheochromocytomas are rare tumors derived from the chromaffin cells of the adrenal medulla.
  • Although these tumors have long been postulated to induce hypertension and cardiomyopathy through the hypersecretion of catecholamines, catecholamines alone may not fully explain the profound myocardial remodeling induced by these tumors.
  • METHODS AND RESULTS: Isolated cardiomyocytes incubated with pheochromocytoma-conditioned growth media contracted at a higher frequency than cardiomyocytes incubated with norepinephrine (NE) only.
  • Sprague-Dawley rats and black-6 mice were implanted with agarose-encapsulated pheochromocytoma (PC12) cells, dihydroxyphenylalanine decarboxylase knock-out PC12 cells deficient in NE (PC12-KO), or NE-secreting pumps.
  • PC12 cell implantation increased left ventricular dilation by 35+/-6% and 9.6+/-1.4% and reduced left ventricular fractional shortening by 20+/-3% and 28+/-4% in rats and mice compared with animals dosed only with NE, respectively.
  • Elimination of NE secretion in PC12-KO cells induced neither cardiac dilation (3.9%+/-1.8% increase versus control) nor changes in (1.9%+/-0.4% reduction) fractional shortening compared to controls.
  • CONCLUSIONS: Pheochromocytomas induce a greater degree of cardiomyopathy than equivalent doses of NE, suggesting pheochromocytoma-induced cardiomyopathy is not solely mediated by NE, rather pheochromocytoma secretory factors in combination with catecholamines act synergistically to induce greater cardiac damage than catecholamines alone.

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Norepinephrine .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Esp Cardiol. 2004 Apr;57(4):347-56 [15104989.001]
  • [Cites] Endocr Rev. 2003 Aug;24(4):539-53 [12920154.001]
  • [Cites] Acta Physiol Acad Sci Hung. 1967;32(1):175-84 [6080429.001]
  • [Cites] Ann N Y Acad Sci. 1969 Jan 31;156(1):285-93 [5291138.001]
  • [Cites] Cancer. 1972 Feb;29(2):327-31 [5013535.001]
  • [Cites] Res Commun Chem Pathol Pharmacol. 1981 Nov;34(2):179-92 [6278551.001]
  • [Cites] Clin Exp Hypertens A. 1982;4(4-5):829-48 [6286177.001]
  • [Cites] Circ Res. 1983 Apr;52(4):471-8 [6131755.001]
  • [Cites] Endocrinology. 1984 Apr;114(4):1272-8 [6323140.001]
  • [Cites] Am Heart J. 1985 Feb;109(2):297-304 [3966346.001]
  • [Cites] J Mol Cell Cardiol. 1985 Apr;17(4):291-306 [3894676.001]
  • [Cites] J Mol Cell Cardiol. 1985 Apr;17(4):349-59 [4020875.001]
  • [Cites] J Mol Cell Cardiol. 1985 Apr;17(4):377-87 [2991539.001]
  • [Cites] Cardiology. 1985;72 Suppl 1:126-30 [2865007.001]
  • [Cites] Heart Vessels. 1985 Aug;1(3):152-7 [3007429.001]
  • [Cites] J Pharmacol Exp Ther. 1987 Apr;241(1):354-60 [2883296.001]
  • [Cites] Am J Cardiovasc Pathol. 1988;1(3):389-99 [3207483.001]
  • [Cites] Jpn J Med. 1990 Jan-Feb;29(1):27-31 [2214343.001]
  • [Cites] Circulation. 1992 Feb;85(2):790-804 [1370925.001]
  • [Cites] J Heart Lung Transplant. 1992 Mar-Apr;11(2 Pt 1):363-6 [1576142.001]
  • [Cites] Ther Immunol. 1994 Aug;1(4):229-46 [7584498.001]
  • [Cites] J Cardiovasc Pharmacol. 1995 Oct;26(4):584-9 [8569219.001]
  • [Cites] Biomaterials. 1996 Feb;17(3):267-75 [8745323.001]
  • [Cites] Circulation. 1998 Mar 31;97(12):1136-43 [9537339.001]
  • [Cites] World J Surg. 1998 Jul;22(7):689-93; discussion 694 [9606283.001]
  • [Cites] Circulation. 1998 Sep 29;98(13):1329-34 [9751683.001]
  • [Cites] Cytokine. 1998 Oct;10(10):739-46 [9811526.001]
  • [Cites] Physiol Rev. 1999 Jan;79(1):215-62 [9922372.001]
  • [Cites] Can J Biochem Physiol. 1959 Jan;37(1):35-42 [13618760.001]
  • [Cites] Am Heart J. 1964 Jul;68:71-90 [14192356.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2005 Jul-Aug;41(7):197-206 [16223334.001]
  • [Cites] Tissue Eng. 2005 Nov-Dec;11(11-12):1797-806 [16411825.001]
  • [Cites] Neurosci Lett. 2006 May 29;400(1-2):75-9 [16503378.001]
  • [Cites] J Hypertens. 2006 Dec;24(12):2331-9 [17082709.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:300-5 [17102099.001]
  • [Cites] Eur J Heart Fail. 2004 Jan;6(1):41-5 [15012917.001]
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] Cardiovasc Res. 2001 Nov;52(2):265-73 [11684074.001]
  • [Cites] Ann N Y Acad Sci. 2002 Oct;971:366-70 [12438154.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2003 Feb;284(2):H626-34 [12388270.001]
  • [Cites] Mol Cell Neurosci. 2003 Jan;22(1):75-86 [12595240.001]
  • [Cites] Clin Chem. 2003 Apr;49(4):586-93 [12651811.001]
  • [Cites] Pol Arch Med Wewn. 2003 Jan;109(1):43-8 [12879765.001]
  • [Cites] Circulation. 2004 Oct 19;110(16):2401-9 [15262835.001]
  • (PMID = 19808327.001).
  • [ISSN] 1941-3297
  • [Journal-full-title] Circulation. Heart failure
  • [ISO-abbreviation] Circ Heart Fail
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL083935-01A1; United States / NHLBI NIH HHS / HL / R01 HL084553; United States / NHLBI NIH HHS / HL / F31 HL083935-01A1; United States / PHS HHS / / R01 49039
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Catecholamines; X4W3ENH1CV / Norepinephrine
  • [Other-IDs] NLM/ NIHMS129904; NLM/ PMC2769512
  •  go-up   go-down


58. Martarelli D, Pompei P, Mazzoni G: Inhibition of adrenocortical carcinoma by diphtheria toxin mutant CRM197. Chemotherapy; 2009;55(6):425-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CRM197 is a non-toxic mutant of diphtheria toxin that binds heparin-binding epidermal growth factor-like growth factor (HB-EGF) which is implicated in the proliferative activity of several tumor cells.
  • AC tumors were implanted in nude mice and then treated with CRM197.
  • A treatment with CRM197 blocked growth, reduced angiogenesis and induced apoptosis in AC tumors implanted in nude mice.
  • CRM197 also inhibited invasion and migration of these tumor cells.
  • CONCLUSIONS: These data support the evidence for anticancer properties of CRM197 in AC tumors.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenocortical Carcinoma / drug therapy. Antineoplastic Agents / pharmacology. Bacterial Proteins / pharmacology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Blotting, Western. Cell Movement / drug effects. Drug Screening Assays, Antitumor. Gene Expression Regulation, Neoplastic. Heparin-binding EGF-like Growth Factor. Humans. Intercellular Signaling Peptides and Proteins / genetics. Male. Mice. Mice, Nude. Neoplasm Transplantation. Neovascularization, Pathologic / drug therapy. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Diphtheria.
  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19996587.001).
  • [ISSN] 1421-9794
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bacterial Proteins; 0 / HBEGF protein, human; 0 / Hbegf protein, mouse; 0 / Heparin-binding EGF-like Growth Factor; 0 / Intercellular Signaling Peptides and Proteins; 92092-36-9 / CRM197 (non-toxic variant of diphtheria toxin)
  •  go-up   go-down


59. Stifelman MD, Fenig DM: Work-up of the functional adrenal mass. Curr Urol Rep; 2005 Feb;6(1):63-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Work-up of the functional adrenal mass.
  • Evaluation of a functional adrenal mass may be initiated based on symptomatic presentation or the detection of an incidental adrenal mass.
  • Recent literature suggests that 10% to 20% of adrenal incidentalomas demonstrate subclinical hormonal dysfunction, which may place patients at a higher risk for metabolic or cardiovascular disorders.
  • Many diagnostic algorithms have been proposed for the evaluation of pheochromocytoma, Cushing's adenoma, aldosteronoma, and hormonally active adrenal cortical carcinoma.
  • In this article, the available literature on functional adrenal masses is reviewed and up-to-date methods of efficient diagnosis are proposed.
  • [MeSH-major] Adenoma / diagnosis. Adrenal Gland Neoplasms / diagnosis. Diagnostic Imaging / methods. Pheochromocytoma / diagnosis
  • [MeSH-minor] Adrenalectomy / methods. Biopsy, Needle. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Neoplasm Staging. Radionuclide Imaging. Risk Assessment. Sensitivity and Specificity. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome. Ultrasonography, Doppler

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1990 Apr 26;322(17):1195-201 [2325710.001]
  • [Cites] Cardiovasc Res. 1998 Jan;37(1):8-13 [9539852.001]
  • [Cites] J Nucl Med. 1985 Jun;26(6):576-85 [2860214.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Feb;88(2):553-8 [12574179.001]
  • [Cites] Am J Med. 1983 Apr;74(4):641-51 [6340491.001]
  • [Cites] Med Clin North Am. 2004 Mar;88(2):443-66 [15049587.001]
  • [Cites] JAMA. 2002 Mar 20;287(11):1427-34 [11903030.001]
  • [Cites] Clin Nucl Med. 1996 Sep;21(9):695-9 [8879869.001]
  • [Cites] Radiology. 1987 Oct;165(1):89-93 [3628794.001]
  • [Cites] J Endocrinol Invest. 1995 Jul-Aug;18(7):495-511 [9221268.001]
  • [Cites] Br J Urol. 1998 Aug;82(2):199-205 [9722754.001]
  • [Cites] N Engl J Med. 1990 Nov 15;323(20):1401-5 [2233907.001]
  • [Cites] Horm Res. 1997;47(4-6):284-9 [9167966.001]
  • [Cites] J Clin Endocrinol Metab. 1979 Jul;49(1):87-91 [447820.001]
  • [Cites] J Urol. 2003 Jan;169(1):5-11 [12478091.001]
  • [Cites] Surg Clin North Am. 2004 Jun;84(3):887-905 [15145241.001]
  • [Cites] Medicine (Baltimore). 1965 Jan;44:37-79 [14264352.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):151-5 [8989250.001]
  • [Cites] J Urol. 2000 Feb;163(2):398-407 [10647642.001]
  • [Cites] N Engl J Med. 1995 Mar 23;332(12):791-803 [7862184.001]
  • [Cites] Ann Intern Med. 2003 Jun 17;138(12):980-91 [12809455.001]
  • [Cites] J Urol. 1995 Dec;154(6):2004-9 [7500445.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):479-91 [14764749.001]
  • [Cites] Endocrinology. 2003 Jun;144(6):2208-13 [12746276.001]
  • [Cites] JAMA. 1993 May 5;269(17):2232-8 [8386285.001]
  • [Cites] Surg Gynecol Obstet. 1986 Sep;163(3):203-8 [3750174.001]
  • [Cites] Curr Urol Rep. 2004 Feb;5(1):73-7 [14733842.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4515-21 [12364428.001]
  • [Cites] Radiol Clin North Am. 1994 Jan;32(1):99-108 [7506835.001]
  • (PMID = 15610699.001).
  • [ISSN] 1527-2737
  • [Journal-full-title] Current urology reports
  • [ISO-abbreviation] Curr Urol Rep
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


60. Bumbuliene Z, Alisauskas J: [Evaluation and treatment of adolescent girls with hirsutism]. Ginekol Pol; 2009 May;80(5):374-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The causes of hirsutism can be various, including familial, idiopathic, and those, caused by excess androgen secretion by the ovary (PCOS, tumors), or by adrenal glands (congenital adrenal hyperplasia, tumor), or exogenous pharmacologic sources of androgens.
  • The diagnosis and treatment of hirsutism remains quite problematic due to innumerous endocrinologic aspects and unsatisfactory treatment results.
  • [MeSH-major] Hirsutism / diagnosis. Hirsutism / drug therapy. Puberty
  • [MeSH-minor] Adolescent. Adolescent Health Services / organization & administration. Androgen Antagonists / therapeutic use. Diagnosis, Differential. Endocrine System Diseases / complications. Endocrine System Diseases / diagnosis. Female. Humans. Hyperandrogenism / complications. Hyperandrogenism / diagnosis. Polycystic Ovary Syndrome / complications. Polycystic Ovary Syndrome / diagnosis

  • MedlinePlus Health Information. consumer health - Puberty.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19548458.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Androgen Antagonists
  • [Number-of-references] 25
  •  go-up   go-down


61. Doddi S, Singhal T, Leake T, Sinha P: Management of an incidentally found large adrenal myelolipoma: a case report. Cases J; 2009;2:8414
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of an incidentally found large adrenal myelolipoma: a case report.
  • Adrenal myelolipoma is a rare benign neoplasm composed of mature adipose and hematopoietic tissue.
  • We would like to present a case report of this rare tumour.
  • Cross-sectional imaging is helpful in making a pre-operative diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Urol. 2004 Jun;11(6):416-8 [15157212.001]
  • [Cites] World J Surg Oncol. 2008;6:72 [18601731.001]
  • [Cites] Radiographics. 1997 Nov-Dec;17(6):1373-85 [9397452.001]
  • [Cites] Endocr Pract. 2007 Oct;13(6):667-71 [17954426.001]
  • [Cites] JBR-BTR. 2008 May-Jun;91(3):90-1 [18661711.001]
  • (PMID = 19918428.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2769438
  •  go-up   go-down


62. Tumino M, Licciardello M, Sorge G, Cutrupi MC, Di Benedetto F, Amoroso L, Catania R, Pennisi M, D'Amico S, Di Cataldo A: Kabuki syndrome and cancer in two patients. Am J Med Genet A; 2010 Jun;152A(6):1536-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this paper we present two patients with Kabuki syndrome and a neoplasm: a child of 6 years with hepatoblastoma and an infant, of 6 months affected by neuroblastoma.
  • [MeSH-major] Abnormalities, Multiple / diagnosis. Adrenal Gland Neoplasms / diagnosis. Facies. Hepatoblastoma / diagnosis. Intellectual Disability / diagnosis. Liver Neoplasms / diagnosis. Neuroblastoma / diagnosis

  • Genetic Alliance. consumer health - Kabuki syndrome.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • [CommentIn] Am J Med Genet A. 2011 Jun;155A(6):1504 [21548020.001]
  • (PMID = 20503331.001).
  • [ISSN] 1552-4833
  • [Journal-full-title] American journal of medical genetics. Part A
  • [ISO-abbreviation] Am. J. Med. Genet. A
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


63. Gross BA, Mindea SA, Pick AJ, Chandler JP, Batjer HH: Medical management of Cushing disease. Neurosurg Focus; 2007;23(3):E10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical management of Cushing disease.
  • Although transsphenoidal excision of the adrenocorticotropic hormone (ACTH)-producing neoplasm is often the treatment of choice in patients with Cushing disease, medical management is itself a useful preoperative temporizing measure, an option for long-term management in nonsurgical candidates, and an option for patients in whom surgery and/or radiotherapy have failed.
  • Three pathophysiologically based approaches exist in the research literature--neuro-modulation to limit ACTH levels, adrenal enzyme inhibition, and glucocorticoid receptor antagonism.
  • Adrenal enzyme inhibitors, however, offer substantial future promise in the management of Cushing disease but are limited by the potential need to use them indefinitely and by dose-tolerance effects.
  • Although etomidate is a potential intravenous alternative for acute cortisol level control, ketoconazole has shown efficacy in the long-term treatment of patients with the disease.

  • COS Scholar Universe. author profiles.
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961023.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Hormone Antagonists; 0 / Neurotransmitter Agents; 0 / Receptors, Glucocorticoid
  • [Number-of-references] 32
  •  go-up   go-down


64. Sephton SE, Dhabhar FS, Keuroghlian AS, Giese-Davis J, McEwen BS, Ionan AC, Spiegel D: Depression, cortisol, and suppressed cell-mediated immunity in metastatic breast cancer. Brain Behav Immun; 2009 Nov;23(8):1148-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Psychological distress and depression, which often accompany cancer diagnosis and treatment, can also suppress or dysregulate endocrine and immune function.
  • CMI is also important for defense against some tumors.
  • [MeSH-major] Breast Neoplasms / immunology. Breast Neoplasms / psychology. Depression / immunology. Depression / psychology. Hydrocortisone / analysis
  • [MeSH-minor] Circadian Rhythm. Female. Humans. Hypothalamo-Hypophyseal System / immunology. Immunity, Cellular. Linear Models. Middle Aged. Neoplasm Metastasis. Patient Selection. Pituitary-Adrenal System / immunology. Psychiatric Status Rating Scales. Saliva / chemistry. Saliva / immunology. Stress, Psychological / immunology

  • Genetic Alliance. consumer health - Depression.
  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Depression.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19643176.001).
  • [ISSN] 1090-2139
  • [Journal-full-title] Brain, behavior, and immunity
  • [ISO-abbreviation] Brain Behav. Immun.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2R001 1 MH/CA47226-06; United States / NIA NIH HHS / AG / 5P01AG018784
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


65. Stigliano A, Cerquetti L, Borro M, Gentile G, Bucci B, Misiti S, Piergrossi P, Brunetti E, Simmaco M, Toscano V: Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane. Endocr Relat Cancer; 2008 Mar;15(1):1-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenocortical Carcinoma / metabolism. Antineoplastic Agents, Hormonal / pharmacology. Biomarkers, Tumor / metabolism. Mitotane / pharmacology. Neoplasm Proteins / metabolism. Proteomics
  • [MeSH-minor] Blotting, Western. Cell Cycle / drug effects. Cell Proliferation / drug effects. Electrophoresis, Gel, Two-Dimensional. Humans. Hydrocortisone / metabolism. Mitochondria / drug effects. Mitochondria / metabolism. Progesterone / metabolism. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Testosterone / metabolism. Tumor Cells, Cultured / drug effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. MITOTANE .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18310271.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 3XMK78S47O / Testosterone; 4G7DS2Q64Y / Progesterone; 78E4J5IB5J / Mitotane; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


66. Wolkersdörfer GW, Marx C, Brown J, Schröder S, Füssel M, Rieber EP, Kuhlisch E, Ehninger G, Bornstein SR: Prevalence of HLA-DRB1 genotype and altered Fas/Fas ligand expression in adrenocortical carcinoma. J Clin Endocrinol Metab; 2005 Mar;90(3):1768-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A distinctive feature of malignant adrenocortical neoplasms is decreased major histocompatibility complex (MHC) class II molecule expression.
  • Therefore, MHC class II phenotype and genotype and expression patterns of the Fas/Fas ligand system were investigated in 24 adrenocortical tumors (n(Adenomas) = 14, n(Carcinomas) = 10) and an adrenal cancer cell line (NCI-H295).
  • Additional studies on MHC class II genotype and phenotype and the altered Fas/Fas ligand system in adrenal neoplasms may help to identify mechanisms of immune escape and suggest new diagnostic approaches.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Adrenocortical Carcinoma / genetics. Antigens, CD95 / metabolism. HLA-DR Antigens / genetics. Membrane Glycoproteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Fas Ligand Protein. Female. Genetic Predisposition to Disease / epidemiology. Genotype. HLA-DRB1 Chains. Humans. Immunohistochemistry. Male. Middle Aged. Prevalence. Risk Factors

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15585555.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / HLA-DR Antigens; 0 / HLA-DRB1 Chains; 0 / Membrane Glycoproteins
  •  go-up   go-down


67. Collins BR: Endocrine diseases of rodents. Vet Clin North Am Exot Anim Pract; 2008 Jan;11(1):153-62, vii-viii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical diagnosis of endocrine diseases almost never occurs in free-ranging animals in their native habitat.
  • Feral animals that have clinical endocrine disease, such as neoplasia, adrenal cortical hyperplasia, or diabetes, would exhibit clinical signs of altered behavior that would result in their removal by predators.
  • The diagnosis of endocrine disease thus takes place in the relatively protective environment of captivity.
  • [MeSH-major] Animals, Domestic. Endocrine System Diseases / veterinary. Rodent Diseases / diagnosis
  • [MeSH-minor] Animals. Cricetinae. Diagnosis, Differential. Female. Gerbillinae. Guinea Pigs. Male. Mice. Rats. Rodentia. Species Specificity

  • MedlinePlus Health Information. consumer health - Endocrine Diseases.
  • MedlinePlus Health Information. consumer health - Pet Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18165143.001).
  • [ISSN] 1094-9194
  • [Journal-full-title] The veterinary clinics of North America. Exotic animal practice
  • [ISO-abbreviation] Vet Clin North Am Exot Anim Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


68. Korpershoek E, Petri BJ, van Nederveen FH, Dinjens WN, Verhofstad AA, de Herder WW, Schmid S, Perren A, Komminoth P, de Krijger RR: Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma. Endocr Relat Cancer; 2007 Jun;14(2):453-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma.
  • Pheochromocytomas (PCCs) are rare tumors that arise from chromaffin tissue in the adrenal medulla, but can also occur in the abdomen outside the adrenals and are then called sympathetic paragangliomas (sPGLs).
  • According to the literature, between 15 and 25% of apparently sporadic adrenal PCC and sPGL are caused by germline mutations in RET, von Hippel-Lindau disease (VHL), succinate dehydrogenase subunit B (SDHB), or subunit D SDHD.
  • However, few studies have addressed the mutationfrequency of these candidate genes in selected subgroups of PCC andsPGL, such as bilateral adrenal PCC or extra-adrenal sPGL, and none have looked at somatic mutations by analyzing tumor tissue.
  • Therefore, we have investigated the occurrence of germline and somatic mutations in RET, VHL, SDHB, and SDHD in comparatively large series of bilateral adrenal PCC (n = 33 patients) and sPGL (n = 26 patients), with the aim of determining the mutation frequency of each of these genes and to establish a genetic testing algorithm.
  • Twenty-one RET, two VHL germline, and one SDHD mutations were found in the patients with bilateral adrenal PCC.
  • We suggest that sequential mutation analysis should be directed first at RET, followed by VHL and SDHD for patients with bilateral adrenal PCC at diagnosis, and at SDHB and SDHD for patients with sPGL.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Genes, Neoplasm. Paraganglioma / genetics. Pheochromocytoma / genetics
  • [MeSH-minor] Adult. Aged. Amino Acid Sequence. Animals. Cattle. DNA Mutational Analysis. Female. Germ-Line Mutation. Humans. Iron-Sulfur Proteins / genetics. Male. Mice. Middle Aged. Molecular Sequence Data. Mutation. Proto-Oncogene Proteins c-ret / genetics. Rats. Succinate Dehydrogenase / genetics. Von Hippel-Lindau Tumor Suppressor Protein / genetics

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639058.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iron-Sulfur Proteins; 0 / SDHD protein, human; EC 1.3.5.1 / SDHB protein, human; EC 1.3.99.1 / Succinate Dehydrogenase; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


69. Schindera ST, Soher BJ, Delong DM, Dale BM, Merkle EM: Effect of echo time pair selection on quantitative analysis for adrenal tumor characterization with in-phase and opposed-phase MR imaging: initial experience. Radiology; 2008 Jul;248(1):140-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of echo time pair selection on quantitative analysis for adrenal tumor characterization with in-phase and opposed-phase MR imaging: initial experience.
  • PURPOSE: To determine the effect of two pairs of echo times (TEs) for in-phase (IP) and opposed-phase (OP) 3.0-T magnetic resonance (MR) imaging on (a) quantitative analysis prospectively in a phantom study and (b) diagnostic accuracy retrospectively in a clinical study of adrenal tumors, with use of various reference standards in the clinical study.
  • Single-breath-hold IP and OP 3.0-T MR images in 21 patients (14 women, seven men; mean age, 63 years) with 23 adrenal tumors (16 adenomas, six metastases, one adrenocortical carcinoma) were reviewed.
  • However, with scheme B, no overlap in the adrenal gland SI-to-liver SI ratio between adenomas and nonadenomas was seen (P < .05).
  • With scheme B, no overlap in adrenal gland SI index-to-liver SI index ratio between adenomas and nonadenomas was seen (P < .05).
  • CONCLUSION: This initial experience indicates SI index is the most reliable parameter for characterization of adrenal tumors with 3.0-T MR imaging when obtaining OP echo before IP echo.
  • [MeSH-major] Adenoma / diagnosis. Adrenal Gland Neoplasms / diagnosis. Echo-Planar Imaging / methods. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2008.
  • (PMID = 18566172.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Silva J, Cachulo Mdo C, Leitão-Marques A: Secondary hypertension to rare adrenal gland tumor. Arq Bras Cardiol; 2010 Dec;95(6):e144-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary hypertension to rare adrenal gland tumor.
  • The ganglioneuroma is a tumor of the sympathetic nervous system and may be associated with hypersecretion of vasoactive substances responsible for various symptoms and signs such as hypertension.
  • The authors report a case of ganglioneuroma and a literature review, focusing on the most important aspects of diagnosis and therapy.
  • The patient had recurrent symptomatic hypertensive crises, having performed an imaging study that found a nodule in the right adrenal gland.
  • As neuroblastic tumors are radiologically undistinguishable, the patient underwent excision, confirming the diagnosis by pathology analysis.
  • [MeSH-major] Adrenal Gland Neoplasms / complications. Ganglioneuroma / complications. Hypertension / etiology


71. Xu J, Wang R, Xie ZH, Odero-Marah V, Pathak S, Multani A, Chung LW, Zhau HE: Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate; 2006 Nov 1;66(15):1664-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis.
  • This study characterized the host microenvironmental role in cancer progression, epithelial to mesenchymal transition (EMT), and bone and adrenal metastasis in parental ARCaP and its derived cell subclones.
  • RESULTS: ARCaP(E) cells, with cobblestone morphology, underwent EMT through cellular interaction with host bone and adrenal gland.
  • Lineage-derived ARCaP(M) cells, with spindle-shape fibroblastic morphology, exhibited decreased cell adhesion and increased metastasis to bone and adrenal gland.
  • CONCLUSIONS: ARCaP uniquely models the molecular basis of prostate cancer bone and adrenal metastases and epithelial to mesenchymal transition.
  • [MeSH-major] Adenocarcinoma / secondary. Adrenal Gland Neoplasms / secondary. Bone Neoplasms / secondary. Epithelial Cells / pathology. Mesoderm / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Animals. Cell Adhesion. Cell Movement. Cell Transformation, Neoplastic / pathology. Clone Cells. Disease Progression. Environment. Humans. Male. Mice. Mice, Nude. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / physiopathology. Neoplasm Transplantation. Organ Specificity / genetics. Tumor Cells, Cultured


72. Leboeuf R, Bénard F, Langlois MF: Thyroid cancer presenting as a PET incidentaloma in a patient with concomitant breast cancer metastases to the thyroid. Clin Nucl Med; 2006 Jul;31(7):382-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Metastases to the thyroid gland are considered a rare cause of thyroid tumor.
  • CASE DESCRIPTION: We describe the case of a 59-year-old woman who presented with simultaneous papillary and breast carcinoma within the thyroid gland.
  • CONCLUSION: This is a rare description of a concomitant papillary thyroid carcinoma presenting as an FDG PET incidentaloma alongside breast cancer metastases to the thyroid gland.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Carcinoma, Papillary / radionuclide imaging. Estrogens. Incidental Findings. Neoplasms, Hormone-Dependent / radionuclide imaging. Neoplasms, Hormone-Dependent / secondary. Neoplasms, Second Primary / radionuclide imaging. Positron-Emission Tomography. Thyroid Neoplasms / radionuclide imaging. Thyroid Neoplasms / secondary
  • [MeSH-minor] Adrenal Gland Neoplasms / secondary. Antineoplastic Agents, Hormonal / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Female. Fluorodeoxyglucose F18. Humans. Iodine Radioisotopes / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Mastectomy, Segmental. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / secondary. Middle Aged. Neoplasm Proteins / analysis. Neoplasms, Radiation-Induced / etiology. Neoplasms, Radiation-Induced / radiography. Neoplasms, Radiation-Induced / radionuclide imaging. Radiopharmaceuticals / therapeutic use. Radiotherapy, Adjuvant. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Tamoxifen / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785803.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogens; 0 / Iodine Radioisotopes; 0 / Neoplasm Proteins; 0 / Radiopharmaceuticals; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 094ZI81Y45 / Tamoxifen; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


73. Aspinall SR, Imisairi AH, Bliss RD, Scott-Coombes D, Harrison BJ, Lennard TW: How is adrenocortical cancer being managed in the UK? Ann R Coll Surg Engl; 2009 Sep;91(6):489-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All tumours were greater than 5 cm in diameter.
  • CONCLUSIONS: The size of tumour, stage and mode of presentation, age and overall survival of patients in this study are comparable to published series of adrenocortical carcinomas from major endocrine surgical centres world-wide.
  • Establishing a database for adrenocortical carcinomas in the UK would contribute to our understanding of the management of this disease.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenocortical Carcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Mitotane / therapeutic use
  • [MeSH-minor] Adrenalectomy / methods. Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Cytotoxins / therapeutic use. Great Britain. Humans. Neoplasm Recurrence, Local. Retrospective Studies. Survival Analysis

  • Hazardous Substances Data Bank. MITOTANE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2001 Jan;57(1):176-82 [11164177.001]
  • [Cites] Arch Pathol (Chic). 1949 Nov;48(5):387-94 [18143915.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1113-21 [11571723.001]
  • [Cites] World J Surg. 2001 Jul;25(7):891-7 [11572030.001]
  • [Cites] World J Surg. 2001 Jul;25(7):914-26 [11572033.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1043-7 [12045859.001]
  • [Cites] ANZ J Surg. 2003 Sep;73(9):727-38 [12956790.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Mar;60(3):273-87 [15008991.001]
  • [Cites] Eur J Endocrinol. 2004 Jun;150(6):789-92 [15191348.001]
  • [Cites] Eur J Endocrinol. 2004 Jun;150(6):809-17 [15191351.001]
  • [Cites] Eur J Cancer Clin Oncol. 1984 Jan;20(1):47-53 [6537915.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):766-73 [3967172.001]
  • [Cites] Surgery. 1992 Dec;112(6):972-9; discussion 979-80 [1455322.001]
  • [Cites] J Pharm Sci. 1995 Feb;84(2):134-8 [7738789.001]
  • [Cites] Radiology. 1995 Nov;197(2):411-8 [7480685.001]
  • [Cites] Surgery. 1996 Feb;119(2):161-70 [8571201.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jul;171(1):201-4 [9648789.001]
  • [Cites] Arch Surg. 1999 Feb;134(2):181-5 [10025460.001]
  • [Cites] Lancet Oncol. 2004 Dec;5(12):718-26 [15581542.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4501-4 [16895957.001]
  • [Cites] N Engl J Med. 2007 Jun 7;356(23):2372-80 [17554118.001]
  • [Cites] N Engl J Med. 2007 Jun 7;356(23):2415-8 [17554125.001]
  • [Cites] Arch Surg. 2001 May;136(5):543-9 [11343545.001]
  • (PMID = 19558758.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Cytotoxins; 78E4J5IB5J / Mitotane
  • [Other-IDs] NLM/ PMC2966201
  •  go-up   go-down


74. Muhlstein J, Rodriguez-Dahlhoff S, Marie B, Fouyssac F: Primary ovarian neuroblastoma. J Pediatr Adolesc Gynecol; 2010 Oct;23(5):263-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The diagnosis of neuroblastoma is rare after the age of 15 years, and anatomical locations are essentially the adrenal glands and paraspinal sites.
  • CASE REPORT: We report the case of a 17-year-old young woman in whom the diagnosis of primary ovarian neuroblastoma associated with a mature teratoma was established.
  • A workup to assess disease extension was negative.
  • Due to the localized characteristic of this tumor and the absence of N-myc oncogene amplification, and in spite of the unfavorable characteristic of the patient's age, treatment consisted of surgical removal of the tumor followed by clinical, laboratory and radiographic monitoring.
  • [MeSH-major] Neoplasms, Second Primary / pathology. Neuroblastoma / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Adolescent. Female. Humans. Neoplasm Staging

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 North American Society for Pediatric and Adolescent Gynecology. Published by Elsevier Inc. All rights reserved.
  • [CommentIn] J Pediatr Adolesc Gynecol. 2010 Oct;23(5):261-2 [20813329.001]
  • (PMID = 20371194.001).
  • [ISSN] 1873-4332
  • [Journal-full-title] Journal of pediatric and adolescent gynecology
  • [ISO-abbreviation] J Pediatr Adolesc Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  •  go-up   go-down


75. Owecki M, Majewska KA, Stawny B, Nikisch E, Drews M, Sowiński J: [Adrenal tumours in a selected 10-years surgical material]. Pol Merkur Lekarski; 2006 Jun;20(120):678-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adrenal tumours in a selected 10-years surgical material].
  • [Transliterated title] Guzy nadnerczy w wybranym 10-letnim materiale operacyjnym.
  • The aim of the study was to analyze the number and proportions of different adrenal tumours resected during the last 10 years in our centre.
  • Besides, we seek correlations between the size of tumours and the age and body mass indexes (BMI) of the examined patients.
  • MATERIAL AND METHODS: The tumours where measured on CT and MRI before surgery, and on pathological examination after resection.
  • In 45 (65.22%) cases the right adrenal was affected, in 21 (30.43%)--the left, in 3 (4.35%)--both.
  • RESULTS: 12 adrenocortical cancers, 20 phaeochromocytomas, 9 cortisol-secreting adenomas, 4 aldosteronomas, 18 hormonally inactive adenomas, 6 miscellaneous tumours were found.
  • Malignant tumours where significantly larger than benign (12.20 +/- 6.81 vs 6.71 +/- 5.62 cm, p < 0.005).
  • We observed no correlation between the age and preoperative tumor size (p = 0.1756), between the age and pathological tumor size (p = 0.3601), and between BMI and the preoperative and histopathologic size (p = 0.4204, and p = 0.6478, respectively).
  • CONCLUSIONS: The most common tumour was phaeochromocytoma.
  • Most tumours where found in the right adrenal.
  • The malignant tumours where larger than benign ones.
  • No correlations between age and BMI, and tumour size where demonstrated.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery
  • [MeSH-minor] Aged. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007266.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


76. Mitterhauser M, Dobrozemsky G, Zettinig G, Wadsak W, Vierhapper H, Dudczak R, Kletter K: Imaging of adrenocortical metastases with [11C]metomidate. Eur J Nucl Med Mol Imaging; 2006 Aug;33(8):974
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnostic imaging. Adrenocortical Carcinoma / diagnostic imaging. Adrenocortical Carcinoma / secondary. Etomidate / analogs & derivatives. Gastrointestinal Neoplasms / diagnostic imaging. Gastrointestinal Neoplasms / secondary. Lung Neoplasms / secondary
  • [MeSH-minor] Humans. Image Enhancement / methods. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / diagnostic imaging. Radionuclide Imaging. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2000 Feb;41(2):275-82 [10688111.001]
  • [Cites] Cancer Biother Radiopharm. 2001 Aug;16(4):289-95 [11602999.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Sep;31(9):1224-30 [15197504.001]
  • (PMID = 16721573.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 5377-20-8 / metomidate; Z22628B598 / Etomidate
  •  go-up   go-down


77. Vassiliadi D, Tsagarakis S: Unusual causes of Cushing's syndrome. Arq Bras Endocrinol Metabol; 2007 Nov;51(8):1245-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although in the majority of the patients with Cushing's syndrome (CS), hypercortisolism is due to ACTH hypersecretion by a pituitary tumour or to ectopic ACTH secretion from an extrapituitary neoplastic lesion or to autonomous cortisol secretion by an adrenal tumour, in occasional patients a much rarer entity may be the cause of the syndrome.
  • (ii) ACTH hypersecretion due to ectopic CRH or CRH-like peptide secretion by various neoplasms;.
  • (iii) ACTH-independent cortisol hypersecretion from ectopic or bilateral adrenal adenomas;.
  • [MeSH-minor] ACTH Syndrome, Ectopic / complications. Adrenal Gland Neoplasms / complications. Female. Glucocorticoids / adverse effects. Humans. Liver Neoplasms / complications. Megestrol Acetate / adverse effects. Ovarian Neoplasms / complications. Pituitary Neoplasms / complications. Ritonavir / adverse effects

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18209862.001).
  • [ISSN] 0004-2730
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Glucocorticoids; O3J8G9O825 / Ritonavir; TJ2M0FR8ES / Megestrol Acetate
  • [Number-of-references] 58
  •  go-up   go-down


78. Tauchmanovà L, Pensabene M, Capuano I, Spagnoletti I, Zeppa P, Del Vecchio S, Mainenti M, De Rosa G, Colao A, Contegiacomo A: Poorly differentiated small cell neuroendocrine carcinoma localized in three different endocrine glands: response to chemotherapy and octreotide LAR. J Endocrinol Invest; 2005 Apr;28(4):371-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorly differentiated small cell neuroendocrine carcinoma localized in three different endocrine glands: response to chemotherapy and octreotide LAR.
  • Neuroendocrine tumors represent a heterogeneous category of neoplasm, with conflicting diagnostic and therapeutic demands.
  • We here describe the case of a 72-yr-old woman with evidence of a poorly differentiated small-cell neuroendocrine carcinoma (NEC) localized in different endocrine glands and other non-endocrine organs.
  • In particular, a large ovarian mass, multinodular thyroid goiter, right adrenal mass, cystic liver metastases and anterior mediastinum lymph node metastasis were present.
  • Diagnosis of poorly differentiated metastasized NEC of unknown origin was made on the basis of histological and immunohistochemical findings, and treatment with etoposide (100 mg/m2 in days 1, 2 and 3) and cisplatinum (45 mg/m2 in days 2 and 3) was initiated.
  • Rapid improvement of dyspnea and a reduction of the largest thyroid nodule, liver metastases and adrenal mass by 50% were observed after 3 months of treatment; the dimensions remained stable thereafter, while the pericardial lymph node disappeared.
  • [MeSH-major] Adrenal Gland Neoplasms / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Liver Neoplasms / secondary. Neoplasms, Unknown Primary / drug therapy. Neuroendocrine Tumors / drug therapy. Octreotide / therapeutic use. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 2004 Jun;25(3):458-511 [15180952.001]
  • [Cites] Genes Chromosomes Cancer. 2000 May;28(1):58-65 [10738303.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):813-29 [9024720.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Mar;48(3):303-9 [9578820.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):429-36 [10027401.001]
  • [Cites] Crit Rev Oncol Hematol. 2001 Jan;37(1):47-51 [11164718.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):463-8 [14713259.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):459-62 [14713258.001]
  • [Cites] Nature. 1993 Jun 3;363(6428):458-60 [8099202.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S47-50 [11762352.001]
  • [Cites] Curr Opin Oncol. 2002 Jan;14(1):38-45 [11790979.001]
  • [Cites] J Exp Clin Cancer Res. 1998 Mar;17(1):3-12 [9646227.001]
  • [Cites] Endocr Relat Cancer. 2004 Mar;11(1):1-18 [15027882.001]
  • [Cites] N Engl J Med. 1999 Aug 26;341(9):635-44 [10460814.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):952-5 [10970700.001]
  • [Cites] Virchows Arch. 1996 Dec;429(6):323-33 [8982376.001]
  • [Cites] Ann Intern Med. 1988 Sep 1;109(5):364-71 [2841895.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):600-6 [10080605.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S111-4 [11762335.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):425-6 [14713254.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1101-7 [11571721.001]
  • [Cites] Gastroenterology. 1999 Mar;116(3):532-42 [10029611.001]
  • [Cites] Endocr Rev. 1991 Nov;12(4):450-82 [1684746.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):858-68 [10080850.001]
  • [Cites] Rev Prat. 2002 Feb 1;52(3):290-6 [11925720.001]
  • [Cites] Am J Pathol. 1993 Mar;142(3):907-15 [8384408.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):227-32 [1712661.001]
  • [Cites] Eur J Cancer. 2001 May;37(8):1014-9 [11334727.001]
  • [Cites] Hum Mol Genet. 1997 Jul;6(7):1169-75 [9215689.001]
  • [Cites] Br J Cancer. 1999 Dec;81(8):1351-5 [10604732.001]
  • [Cites] J R Coll Surg Edinb. 2002 Apr;47(2):495-9 [12018694.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 1;89(19):1448-53 [9326914.001]
  • (PMID = 15966513.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; RWM8CCW8GP / Octreotide
  •  go-up   go-down


79. Nishiuchi T, Imachi H, Fujiwara M, Murao K, Onishi H, Kiguchi T, Takimoto H, Kushida Y, Haba R, Ishida T: A case of non-Hodgkin's lymphoma primary arising in both adrenal glands associated with adrenal failure. Endocrine; 2009 Feb;35(1):34-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of non-Hodgkin's lymphoma primary arising in both adrenal glands associated with adrenal failure.
  • It is known that adrenal insufficiency is one of the complications in primary adrenal lymphoma, especially those with bilateral adrenal involvement.
  • The patient was transferred to our hospital for evaluation of bilateral adrenal tumors and hyponatremia.
  • He was diagnosed as having non-Hodgkin's lymphoma (NHL) with primaries arising in both adrenal glands.
  • Primary adrenal lymphoma (PAL) is a rare extra-nodal NHL.
  • Although an appropriate treatment of this disease has not been established, our case has demonstrated that the combination of rituximab and THP-COP chemotherapy could be administered, and that it improved clinical manifestations.
  • This case raises the suggestion that malignant lymphoma should be suspected in patients with bilateral adrenal tumors that present with progressive adrenal insufficiency.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Insufficiency / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Neoplasms, Multiple Primary / diagnosis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Intern Med. 2003 Jul;42(7):609-14 [12879956.001]
  • [Cites] Ann Hematol. 2004 Jul;83(7):460-3 [14730391.001]
  • [Cites] Int J Hematol. 2005 Apr;81(3):246-54 [15814336.001]
  • [Cites] Rev Esp Enferm Dig. 2007 Aug;99(8):471-4 [18020866.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jan;56(1):95-101 [11849252.001]
  • [Cites] Postgrad Med J. 1985 Jul;61(717):637-9 [4022898.001]
  • [Cites] Clin Nucl Med. 2005 Apr;30(4):222-30 [15764875.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Medicine (Baltimore). 1961 Feb;40:31-84 [13743408.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • (PMID = 19002613.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Babińska A, Gnacińska A, Swiatkowska-Stodulska R, Sworczak K: Myocardial infarction in a 30-year-old patient with pheochromocytoma and type 1 neurofibromatosis. Pol Arch Med Wewn; 2008 Sep;118(9):517-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chromaffinoma of the adrenal medulla (pheochromocytoma--PHEO) is a rare cause of arterial hypertension which is diagnosed incidentally or run in a family as a component of disease syndromes of the genetic origin.
  • A correct diagnosis of PHEO allows the right treatment to be administered.
  • The evaluation of the secondary arterial hypertension led to the detection of the adrenal tumor.
  • Based on the clinical presentation and the tumor characteristics, on computed tomography, PHEO was suspected.
  • The patient underwent laparoscopic, right-sided adrenalectomy, and the histopathological examination definitely concurred with the diagnosis of PHEO.
  • The diagnosis toward PHEO is recommended if the patient with NF1 shows arterial hypertension.
  • Proper diagnosis and treatment protects the patient against life-threatening cardiovascular complications.
  • [MeSH-major] Adrenal Gland Neoplasms / complications. Myocardial Infarction / diagnosis. Myocardial Infarction / etiology. Neurofibromatosis 1 / complications. Pheochromocytoma / complications


81. Perrochia H, Delfour C: [An adrenal tumor]. Ann Pathol; 2008 Feb;28(1):49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An adrenal tumor].
  • [Transliterated title] Une tumeur de la surrénale.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / surgery
  • [MeSH-minor] Adipose Tissue / pathology. Adrenal Cortex / pathology. Adrenal Cortex Neoplasms / pathology. Adrenal Cortex Neoplasms / surgery. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538716.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


82. Cecchetto G, Riccipetitoni G, Inserra A, Esposito C, Michelazzi A, Ruggeri G, Spinelli C, Lima M, Italian Group of Pediatric Surgical Oncology: Minimally-invasive surgery in paediatric oncology: proposal of recommendations. Pediatr Med Chir; 2010 Sep-Oct;32(5):197-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the exact role of MIS in Paediatric Oncology is still not completely defined, a restrict panel of Italian Paediatric Surgeons, some interested in Oncologic Surgery, others in MIS, prepared a schematic document, mainly founded on literature data, to provide Paediatric Surgeons with recommendations useful to approach paediatric tumours with MIS.
  • The Authors summarize the feasibility of MIS, when performed with different purposes (biopsy / resection) and timing (initial / delayed surgery) for the most common solid tumours in children.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Liver Neoplasms / surgery. Lung Neoplasms / surgery. Lymphoma / surgery. Minimally Invasive Surgical Procedures. Neuroblastoma / surgery. Ovarian Neoplasms / surgery. Sarcoma / surgery. Thyroid Neoplasms / surgery
  • [MeSH-minor] Biopsy. Child. Female. Humans. Italy. Male. Neoplasm Staging


83. Siriwong S, Shuangshoti S, Saritsiri S, Pak-art P, Khovidhunkit W, Snabboon T: Functioning adrenocortical carcinoma with superior vena cava and upper airway obstructions. J Med Assoc Thai; 2006 Sep;89(9):1511-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Typically, the tumor is large and has regional invasion or distant metastasis at initial presentation.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Airway Obstruction / pathology. Vena Cava, Superior / pathology
  • [MeSH-minor] Adult. Cushing Syndrome / diagnosis. Fatal Outcome. Humans. Male. Neoplasm Invasiveness. Neoplasm Metastasis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • MedlinePlus Health Information. consumer health - Choking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17100393.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


84. Bissada NK, Safwat AS, Seyam RM, Al Sobhi S, Hanash KA, Jackson RJ, Sakati N, Bissada MA: Pheochromocytoma in children and adolescents: a clinical spectrum. J Pediatr Surg; 2008 Mar;43(3):540-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The purpose of the study was to identify the spectrum of disease characteristics of pheochromocytoma in children.
  • Tumors were localized by imaging studies and all were confirmed pathologically.
  • Patients included 17 with adrenal and 4 with extra-adrenal tumors including 1 in the urinary bladder.
  • One patient with malignant pheochromocytoma died of the disease, and 1 with recurrent pheochromocytoma had neurologic consequences.
  • To our knowledge, this series is one of the largest reports of adrenal pheochromocytoma in children.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / surgery. Pheochromocytoma / diagnosis. Pheochromocytoma / surgery
  • [MeSH-minor] Adolescent. Adrenalectomy / methods. Age Factors. Biopsy, Needle. Child. Child, Preschool. Cohort Studies. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Neoplasm Staging. Neurosurgery. Phenoxybenzamine / therapeutic use. Retrospective Studies. Risk Assessment. Sex Factors. Sickness Impact Profile. Survival Rate. Treatment Outcome


85. Jhala NC, Eltoum IA, Eloubeidi MA, Meara R, Chhieng DC, Crowe DR, Jhala D: Providing on-site diagnosis of malignancy on endoscopic-ultrasound-guided fine-needle aspirates: should it be done? Ann Diagn Pathol; 2007 Jun;11(3):176-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Providing on-site diagnosis of malignancy on endoscopic-ultrasound-guided fine-needle aspirates: should it be done?
  • BACKGROUND: Rapid and accurate tissue diagnosis for a deep-seated malignancy would allow treating physicians to provide disease-specific interventions and help patients make early informed management decisions.
  • Providing on-site tissue diagnosis for fine-needle aspirate samples obtained with endosonography would help develop such efficient patient management issues.
  • Here we report our experience of prospectively providing on-site diagnosis on 485 endoscopic ultrasound fine-needle aspirate samples.
  • METHODS: Four hundred eighty-five endoscopic ultrasound fine-needle aspirates from the pancreas (n= 305), lymph nodes (n = 91), biliary tree (n = 47), liver (n = 15), gastrointestinal tract (n = 19), and adrenal gland (n = 8) were reviewed.
  • RESULTS: Of the 485 cases, 163 (33.6%) were diagnosed as benign, 43 (8.8%) as atypical, 21 (4.3%) as suspicious, 18 (3.7%) as positive for neoplasm, and 230 (47.4%) as malignant after final cytologic interpretation.
  • A significantly (P < .001) higher degree of concordance was noted for unequivocal diagnosis of malignancy (196/198, 98.9%) vs nonmalignancy (200/250, 67.2%) between on-site and final cytologic diagnosis.
  • Of the 52 discordant cases, 12 (2.6%) diagnoses were downgraded and 40 (8.9%) were upgraded from preliminary on-site diagnosis.
  • Our overall sensitivity (87 vs 92), specificity (95% vs 100%), and accuracy (90% vs 94%) improved for final cytologic diagnosis.
  • CONCLUSION: On-site diagnosis of malignancy could be used to initiate informed patient management decisions.
  • Cases where a diagnosis of malignancy is not rendered at on-site interpretation need further cytologic evaluation.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Endosonography / methods. Neoplasms / diagnosis
  • [MeSH-minor] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / pathology. Adult. Aged. Aged, 80 and over. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / pathology. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / pathology. Middle Aged. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology. Retrospective Studies. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17498591.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Sano H, Gonzalez-Gomez I, Wu SQ, Armenian SH, Jubran RF, Shimada H: A case of composite neuroblastoma composed of histologically and biologically distinct clones. Pediatr Dev Pathol; 2007 May-Jun;10(3):229-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of a 12-month-old girl with stage 3 neuroblastoma composed of 2 distinct clones in the adrenal primary tumor.
  • It is well documented that tumors in the Ganglioneuroblastoma, nodular (composite, Schwannian stroma-rich/stroma-dominant and stroma-poor) category are composite and composed of multiple clones.
  • To our knowledge, however, this is the 1st case report of composite tumor with biologically favorable and unfavorable clones in the Neuroblastoma (Schwannian stroma-poor) category.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Neuroblastoma / pathology
  • [MeSH-minor] Clone Cells. Female. Ferritins / blood. Homovanillic Acid / urine. Humans. In Situ Hybridization, Fluorescence. Infant. L-Lactate Dehydrogenase / blood. Neoplasm Staging. Nuclear Proteins / metabolism. Oncogene Proteins / metabolism. Treatment Outcome. Vanilmandelic Acid / urine

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17535087.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYCN protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins; 55-10-7 / Vanilmandelic Acid; 9007-73-2 / Ferritins; EC 1.1.1.27 / L-Lactate Dehydrogenase; X77S6GMS36 / Homovanillic Acid
  •  go-up   go-down


87. Huang TW, Tzao C, Chen DW, Tsai WC, Cheng YL, Lee SC: Lung cancer with isolated skip metastasis to an abdominal lymph node. Onkologie; 2007 Jul;30(7):375-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The preferential sites of extrapulmonary spread include lymph nodes, liver, brain, adrenal gland, and bone.
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Lung Neoplasms / diagnostic imaging. Lymphatic Metastasis / diagnostic imaging. Positron-Emission Tomography
  • [MeSH-minor] Abdomen. Biopsy. Female. Fluorodeoxyglucose F18. Humans. Incidental Findings. Lung / diagnostic imaging. Lung / pathology. Lymph Node Excision. Lymph Nodes / diagnostic imaging. Lymph Nodes / pathology. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Onkologie. 2007 Jul;30(7):352 [17596742.001]
  • [CommentIn] Onkologie. 2008 Dec;31(12):708 [19060511.001]
  • (PMID = 17596746.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


88. Quackenbush KE, Luna-Fineman S, Magee JF, Gundogan M, Golobi M, Irie T, Fernandez CV: Neuroblastoma involvement of the falx cerebri. Pediatr Blood Cancer; 2009 Dec 15;53(7):1337-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dura Mater / pathology. Meningeal Neoplasms / secondary. Neuroblastoma / secondary
  • [MeSH-minor] Adrenalectomy. Carboplatin / administration & dosage. Cell Lineage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Infant. Infant, Newborn. Male. Microphthalmia-Associated Transcription Factor / genetics. Neoplasm Staging. Neural Crest. Pulmonary Veins / abnormalities. Remission Induction. Skin Neoplasms / drug therapy. Skin Neoplasms / secondary. Waardenburg Syndrome / complications. Waardenburg Syndrome / genetics

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19821537.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MITF protein, human; 0 / Microphthalmia-Associated Transcription Factor; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


89. Schimmer BP, Cordova M, Cheng H, Tsao A, Morris Q: A genome-wide assessment of adrenocorticotropin action in the Y1 mouse adrenal tumor cell line. Mol Cell Endocrinol; 2007 Feb;265-266:102-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A genome-wide assessment of adrenocorticotropin action in the Y1 mouse adrenal tumor cell line.
  • This report summarizes the genome-wide effects of ACTH on transcript accumulation in mouse adrenal Y1 cells and the relative contributions of the cAMP-, protein kinase C- and Ca(2+)-dependent signaling pathways to these actions of the hormone.
  • Collectively, our results suggest that Y1 adrenal cells undergo extensive remodeling upon prolonged stimulation with ACTH.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Adrenocorticotropic Hormone / metabolism. Genome
  • [MeSH-minor] Animals. Cell Line, Tumor. Humans. Mice. Oligonucleotide Array Sequence Analysis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17207920.001).
  • [ISSN] 0303-7207
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone
  • [Number-of-references] 33
  •  go-up   go-down


90. Lane BR, Tiong HY, Campbell SC, Fergany AF, Weight CJ, Larson BT, Novick AC, Flechner SM: Management of the adrenal gland during partial nephrectomy. J Urol; 2009 Jun;181(6):2430-6; discussion 2436-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of the adrenal gland during partial nephrectomy.
  • The indications for adrenalectomy in patients undergoing partial nephrectomy are not clearly defined and some surgeons perform it routinely for large and/or upper pole renal tumors.
  • We analyzed initial management and oncological outcomes of adrenal glands after open partial nephrectomy.
  • During partial nephrectomy the ipsilateral adrenal gland was resected if a suspicious adrenal nodule was noted on radiographic imaging, or if intraoperative findings indicated direct extension or metastasis.
  • Pathological analysis revealed direct invasion of the adrenal gland by renal cell carcinoma (1), renal cell carcinoma metastasis (2), other adrenal neoplasms (3) or benign tissue (42, 87%).
  • Metachronous adrenalectomy was ipsilateral (10), contralateral (2) or bilateral (3), revealing metastatic renal cell carcinoma in 11 patients.
  • CONCLUSIONS: Adrenalectomy should not be routinely performed during partial nephrectomy, even for upper pole tumors.
  • We propose concomitant adrenalectomy only if a suspicious adrenal lesion is identified radiographically or invasion of the adrenal gland is suspected intraoperatively.
  • Even using such strict criteria only 13% of these suspicious adrenal nodules contained cancer.
  • The rarity of metachronous adrenal metastasis and the lack of an observable benefit to concomitant adrenalectomy support adrenal preservation during partial nephrectomy except as previously outlined.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenalectomy. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Nephrectomy / methods
  • [MeSH-minor] Adrenal Glands. Aged. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19371896.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Scharmach M, Neumann V, Müller KM, Fischer M: [Comparison of patterns of metastasis between malignant pleural mesotheliomas and pulmonary carcinomas]. Pneumologie; 2006 May;60(5):277-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Vergleich der Metastasierungsmuster maligner Pleuramesotheliome und pulmonaler Karzinome.
  • Starting with the question whether there is a principal difference in the metastatic behaviour of pleural mesothelioma and pulmonary tumors, a detailed retrospective study of the findings of 210 post-mortem examinations between the years of 1992 to 1999 was conducted.
  • There is no significant difference in the TMN-staging between both tumor groups at the time of death.
  • One exception was the brain: there were significantly more metastases from the pulmonary tumors.
  • Carcinomas metastasized more frequently into the skeleton, the kidneys and the adrenal glands, while metastases of mesotheliomas were more often found in the peritoneum.
  • As of the moment there is no significant difference in the pattern of metastasis between both tumor groups discernible.
  • [MeSH-major] Carcinoma / pathology. Lung Neoplasms / pathology. Mesothelioma / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Cadaver. Diagnosis, Differential. Humans. Neoplasm Metastasis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16703480.001).
  • [ISSN] 0934-8387
  • [Journal-full-title] Pneumologie (Stuttgart, Germany)
  • [ISO-abbreviation] Pneumologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


92. Khochikar MV: Management of urological cancers during pregnancy. Nat Rev Urol; 2010 Apr;7(4):195-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As these tumors are very rare among pregnant women and their symptoms might mimic those of common pregnancy-related disorders, the diagnosis is often delayed.
  • Once a urological tumor is diagnosed in a pregnant patient, appropriate steps should be taken to treat her and the fetus at the same time.
  • Common urological cancers that might occur during pregnancy include renal cancer, bladder cancer and adrenal tumors, particularly pheochromocytoma.
  • [MeSH-major] Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / surgery. Urologic Neoplasms / diagnosis. Urologic Neoplasms / surgery
  • [MeSH-minor] Animals. Disease Management. Female. Humans. Pregnancy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Rev Urol. 2010 Jul;7(7):doi:10.1038/nrurol.2010.25-c1 [20665982.001]
  • (PMID = 20212515.001).
  • [ISSN] 1759-4820
  • [Journal-full-title] Nature reviews. Urology
  • [ISO-abbreviation] Nat Rev Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 85
  •  go-up   go-down


93. Ferreira U, Nardi Pedro R, Matheus WE, Prudente A, Mendonça Borges G, Rodrigues Netto N Jr: Open surgical treatment of right-sided adrenal carcinomas &gt;15 cm. Urol Int; 2007;78(1):46-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Open surgical treatment of right-sided adrenal carcinomas >15 cm.
  • INTRODUCTION: Adrenal carcinomas are rare and are associated with a very poor prognosis.
  • The purpose of this paper is to present a single-institution experience in excising right-sided giant adrenal carcinomas, discussing the difficulties and the usage of special surgical devices to facilitate the procedure.
  • PATIENTS AND METHODS: During June 2001 to June 2003, 18 patients with right-sided adrenal tumors were treated at the State University of Campinas Hospital--UNICAMP.
  • RESULTS: Adrenal cortical carcinoma was the histological diagnosis according to the Weiss criteria; no positive surgical margin was detected, even in those patients with invasion of the hepatic capsule.
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17192732.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


94. Fox NS, Streltzoff J, Chasen ST: Spontaneous resolution of an adrenal mass seen on ultrasound at 17 weeks gestation. J Pediatr Hematol Oncol; 2008 May;30(5):405-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous resolution of an adrenal mass seen on ultrasound at 17 weeks gestation.
  • We report a congenital neuroblastoma with findings at 17 weeks gestation that was managed expectantly; this represents the earliest reported finding of a congenital neuroblastoma we could find in the English literature.
  • [MeSH-major] Adrenal Gland Neoplasms / embryology. Neoplasm Regression, Spontaneous. Neuroblastoma / embryology. Pregnancy Trimester, Second

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458580.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Gonsior A, Pfeiffer H, Führer D, Liatsikos E, Schwalenberg T, Stolzenburg JU: [Adrenal tumors. Principles of diagnostics and operative treatment]. Urologe A; 2010 May;49(5):659-68; quiz 669-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adrenal tumors. Principles of diagnostics and operative treatment].
  • [Transliterated title] Nebennierentumoren. Grundlagen der Diagnostik und operativen Therapie.
  • Adrenal masses are very heterogeneous and comprise benign or malignant tumors, unilateral or bilateral masses and variable endocrine activity.
  • Because of these attributes adrenal gland masses are a clinical challenge.
  • This article gives a summary of diagnostic steps and indications for adrenal surgery including perioperative management.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / surgery
  • [MeSH-minor] Adrenal Gland Diseases / diagnosis. Adrenal Gland Diseases / surgery. Adrenal Hyperplasia, Congenital / diagnosis. Adrenal Hyperplasia, Congenital / surgery. Adrenalectomy / instrumentation. Adrenalectomy / methods. Adrenogenital Syndrome / diagnosis. Adrenogenital Syndrome / surgery. Chemotherapy, Adjuvant. Combined Modality Therapy. Cushing Syndrome / diagnosis. Cushing Syndrome / surgery. Diagnosis, Differential. Diagnostic Imaging. Humans. Hyperaldosteronism / diagnosis. Hyperaldosteronism / surgery. Laparoscopes. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / radiotherapy. Neoplasms, Multiple Primary / surgery. Pheochromocytoma / diagnosis. Pheochromocytoma / surgery. Radiotherapy, Adjuvant. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Internist (Berl). 2006 Sep;47(9):953-9 [16823578.001]
  • [Cites] Urology. 1997 Jul;50(1):19-24 [9218013.001]
  • [Cites] Endocr Relat Cancer. 2005 Sep;12(3):667-80 [16172199.001]
  • [Cites] Urology. 2008 Jun;71(6):1138-41 [18336879.001]
  • [Cites] Ann Intern Med. 2003 Mar 4;138(5):424-9 [12614096.001]
  • [Cites] J Urol. 2001 Jul;166(1):38-41 [11435818.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2027-37 [16551738.001]
  • [Cites] Endocr Relat Cancer. 2007 Sep;14(3):587-99 [17914090.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Sep;93(9):3266-81 [18552288.001]
  • [Cites] J Urol. 2001 Aug;166(2):429-36 [11458042.001]
  • [Cites] Lancet. 2006 May 13;367(9522):1605-17 [16698415.001]
  • [Cites] Internist (Berl). 2007 Sep;48(9):971-86 [17684715.001]
  • [Cites] Clin Cancer Res. 2009 Oct 15;15(20):6378-85 [19825962.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Apr;13(2):106-10 [12709616.001]
  • [Cites] J Clin Endocrinol Metab. 2008 May;93(5):1526-40 [18334580.001]
  • [Cites] J Endocrinol Invest. 2004 Apr;27(4):387-99 [15233562.001]
  • [Cites] Urologe A. 2008 Feb;47(2):172-81 [18030443.001]
  • [Cites] N Engl J Med. 2002 May 9;346(19):1459-66 [12000816.001]
  • [Cites] Endocr Rev. 2004 Apr;25(2):309-40 [15082524.001]
  • [Cites] Eur Urol. 2010 May;57(5):873-8 [20137850.001]
  • [Cites] Internist (Berl). 2009 Oct;50(10):1202, 1204, 1206 passim [19707731.001]
  • [Cites] Endocrinol Metab Clin North Am. 2000 Mar;29(1):43-56 [10732263.001]
  • (PMID = 20449781.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


96. Ho YH, Yap WM, Chuah KL: Solitary fibrous tumor of the adrenal gland with unusual immunophenotype: a potential diagnostic problem and a brief review of endocrine organ solitary fibrous tumor. Endocr Pathol; 2010 Jun;21(2):125-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the adrenal gland with unusual immunophenotype: a potential diagnostic problem and a brief review of endocrine organ solitary fibrous tumor.
  • Solitary fibrous tumor was initially thought to be a pleura-based tumor.
  • Nonetheless, a primary involvement of the endocrine organs is rare, and in this report, we detail an instance where the tumor affected the adrenal gland of a 71-year-old Arab man.
  • On histology, besides the typical morphologic features seen in solitary fibrous tumor, the neoplasm also exhibited unusual features on immunohistochemistry such as positive staining for cytokeratin AE1/3 and calponin in conjunction with diffuse expression for S-100.
  • The genetic tests for t(X:18) as seen in synovial sarcoma were negative, and the overall histological appearance favored a diagnosis of solitary fibrous tumor.
  • To the best of our knowledge, this report represents the fifth case of a solitary fibrous tumor primarily occurring in the adrenal gland.
  • The differential diagnoses of this neoplasm in our case and a brief summary of solitary fibrous tumor primarily involving the various endocrine organs are presented.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Solitary Fibrous Tumors / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Dec;30(12):1464-73 [10667425.001]
  • [Cites] Endocr Pathol. 2009 Spring;20(1):56-61 [19224406.001]
  • [Cites] Ann Diagn Pathol. 2009 Oct;13(5):339-43 [19751911.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1434-40 [12409719.001]
  • [Cites] Am J Surg Pathol. 2008 Jul;32(7):1080-7 [18520439.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12 ):1501-11 [9850176.001]
  • [Cites] Urology. 2007 Sep;70(3):591.e5-7 [17905130.001]
  • [Cites] Histopathology. 1997 Dec;31(6):568-76 [9447390.001]
  • [Cites] Mod Pathol. 1996 Dec;9(12):1170-4 [8972477.001]
  • [Cites] Histopathology. 2004 Nov;45(5):539-40 [15500659.001]
  • [Cites] Laryngoscope. 2009 Dec;119(12):2306-8 [19806654.001]
  • [Cites] Pathol Res Pract. 2010 Jan 15;206(1):59-65 [19369012.001]
  • [Cites] Virchows Arch. 2000 Oct;437(4):445-9 [11097372.001]
  • [Cites] Virchows Arch. 2005 Jul;447(1):81-6 [15926073.001]
  • [Cites] AJR Am J Roentgenol. 2007 Jun;188(6):W512-4 [17515340.001]
  • [Cites] Thyroid. 2007 Feb;17(2):119-26 [17316113.001]
  • [Cites] Histopathology. 2003 Jun;42(6):588-93 [12786895.001]
  • [Cites] Am J Surg Pathol. 2006 May;30(5):630-4 [16699318.001]
  • [Cites] Endocr Pathol. 2007 Winter;18(4):239-43 [18197480.001]
  • [Cites] World J Surg. 2004 Nov;28(11):1176-9 [15490056.001]
  • [Cites] Ultrastruct Pathol. 2009 Jul-Aug;33(4):165-8 [19728233.001]
  • [Cites] Ann Diagn Pathol. 2003 Jun;7(3):169-73 [12808569.001]
  • (PMID = 20191330.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


97. Kauhanen S, Seppänen M, Ovaska J, Minn H, Bergman J, Korsoff P, Salmela P, Saltevo J, Sane T, Välimäki M, Nuutila P: The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocr Relat Cancer; 2009 Mar;16(1):255-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors.
  • The study was set up to determine the clinical value of dihydroxyphenylalanine positron emission tomography-computed tomography ([(18)F]DOPA PET-CT) in patients with neuroendocrine tumors (NETs).
  • Patients were divided into two groups: primary diagnosis/staging and restaging of disease.
  • All patients without previous diagnosis of NET had biochemical proof of disease.
  • In patients having PET for primary diagnosis/staging (n=32), the accuracy of PET was 88%, and for restaging 92% (n=61).
  • In organ-region-specific analysis, the sensitivity and specificity were 100% in the primary diagnosis of pheochromocytoma (n=16) and metastases were found in all cases with recurrent disease (n=5).
  • In analysis of patients with biochemical proof of disease combined with negative conventional imaging methods, PET had positive and negative predictive value of 92% and 95% respectively.
  • [(18)F]DOPA PET-CT provided important additional information in the diagnosis of pheochromocytoma and restaging of known NET.
  • Both in primary diagnosis and in patients with formerly known NET and increasing tumor markers, [(18)F]DOPA PET-CT is a sensitive first-line imaging method.
  • [MeSH-major] Fluorodeoxyglucose F18. Neoplasm Staging / methods. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / radionuclide imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / radionuclide imaging. Adult. Carcinoma, Medullary / pathology. Carcinoma, Medullary / radionuclide imaging. False Negative Reactions. False Positive Reactions. Female. Gastrointestinal Neoplasms / pathology. Gastrointestinal Neoplasms / radionuclide imaging. Humans. Male. Middle Aged. Pheochromocytoma / pathology. Pheochromocytoma / radionuclide imaging. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity. Thyroid Neoplasms / pathology. Thyroid Neoplasms / radionuclide imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Endocr Relat Cancer. 2009 Jun;16(2):661
  • (PMID = 19088184.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


98. Chesnokova V, Melmed S: Pituitary tumour-transforming gene (PTTG) and pituitary senescence. Horm Res; 2009 Apr;71 Suppl 2:82-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary tumour-transforming gene (PTTG) and pituitary senescence.
  • Pituitary tumours account for 15% of intracranial neoplasms and are benign monoclonal neoplasms that may be clinically silent or secrete hormones, including prolactin, growth hormone, adrenocorticotrophic hormone or, rarely, thyroid-stimulating hormone or gonadotrophins.
  • Our results provide further insights into the role of cell-cycle control and growth constraints on experimental and human pituitary tumours, which underlie their failure to progress to malignancy.
  • These results improve our understanding of pituitary syndromes associated with infertility, growth disorders, hypercortisolism or adrenal, thyroid and gonadal failure due to abrogated pituitary function.
  • [MeSH-major] Brain Neoplasms / metabolism. Cell Aging. Cell Cycle. Mutation. Neoplasm Proteins / metabolism. Pituitary Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19407503.001).
  • [ISSN] 1423-0046
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Pituitary Hormones; 0 / Retinoblastoma Protein; 0 / Securin; 0 / pituitary tumor-transforming protein 1, human
  • [Number-of-references] 38
  •  go-up   go-down


99. Gourley C, Michie CO, Roxburgh P, Yap TA, Harden S, Paul J, Ragupathy K, Todd R, Petty R, Reed N, Hayward RL, Mitchell P, Rye T, Schellens JH, Lubinski J, Carmichael J, Kaye SB, Mackean M, Ferguson M: Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. J Clin Oncol; 2010 May 20;28(15):2505-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Genes, BRCA1. Genes, BRCA2. Germ-Line Mutation. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adrenal Gland Neoplasms / genetics. Adrenal Gland Neoplasms / secondary. Adult. Aged. Aged, 80 and over. Brain Neoplasms / genetics. Brain Neoplasms / secondary. Female. Genetic Predisposition to Disease. Humans. Incidence. Liver Neoplasms / genetics. Liver Neoplasms / secondary. Lung Neoplasms / genetics. Lung Neoplasms / secondary. Middle Aged. Neoplasm Metastasis. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / secondary. Phenotype. Scotland. Splenic Neoplasms / genetics. Splenic Neoplasms / secondary

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20406939.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / ; United Kingdom / Chief Scientist Office / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


100. Orlando R, Lirussi F: Development of mantle cell lymphoma in a patient with adrenocortical carcinoma and an 18-year survival after complete removal of the primary cancer and resection of local recurrences. Anticancer Res; 2006 Mar-Apr;26(2B):1563-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, fifteen years after the complete resection of the primary neoplasm, the patient first developed an autoimmune thrombocytopenic purpura and later a mantle cell lymphoma located in the mediastinal lymph nodes.
  • This case confirms the possible growth of a second tumour in patients with adrenocortical carcinomas, especially if presenting a long survival after resection of the primary malignancy, and emphasises the need for the close follow-up of these patients.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / surgery. Lymphoma, Mantle-Cell / diagnosis. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary / diagnosis

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619572.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down






Advertisement